antitubercular agent - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	antitubercular agent	go back to main search page
Accession:	CHEBI:33231	browse the term
Definition:	A substance that kills or slows the growth of Mycobacterium tuberculosis and is used in the treatment of tuberculosis.
Synonyms:	related_synonym:	antitubercular; antitubercular agents; antitubercular drug; antitubercular drugs; tuberculostatic agent

show annotations for term's descendants Sort by:
Rat (603) Mouse (609) Human (633) Chinchilla (0) Bonobo (0) Dog (2) Squirrel (0) Pig (1) Green Monkey (0) Naked Mole-rat (0) All
Genes (603)

4-aminosalicylic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

bone morphogenetic protein 6

increases expression

Aminosalicylic Acid results in increased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

epiregulin

increases expression

Aminosalicylic Acid results in increased expression of EREG mRNA

NCBI chr14:17,027,287...17,041,062
Ensembl chr14:17,027,287...17,041,062

G

interleukin 24

increases expression

Aminosalicylic Acid results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Aminosalicylic Acid results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

N-acetyltransferase 1

increases acetylation

NAT1 protein results in increased acetylation of Aminosalicylic Acid

PMID:15627487 PMID:16003948

NCBI chr16:22,218,217...22,238,516
Ensembl chr16:22,208,194...22,238,520

G

N-acetyltransferase 2

multiple interactions

[Peroxynitrous Acid results in decreased activity of NAT2 protein] which results in decreased acetylation of Aminosalicylic Acid

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

phosphotyrosine interaction domain containing 1

increases expression

Aminosalicylic Acid results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

solute carrier family 7 member 11

increases expression

Aminosalicylic Acid results in increased expression of SLC7A11 mRNA

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

increases expression

Aminosalicylic Acid results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

D-cycloserine

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 1A

multiple interactions

Cycloserine inhibits the reaction [ABCB1 protein results in decreased susceptibility to Doxorubicin]

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

DNA-damage inducible transcript 3

multiple interactions

Cycloserine inhibits the reaction [resveratrol results in increased expression of DDIT3 protein]

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

early growth response 1

increases expression

Cycloserine results in increased expression of EGR1 protein

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

Fos proto-oncogene, AP-1 transcription factor subunit

multiple interactions

Cycloserine promotes the reaction [Clozapine results in increased expression of FOS mRNA]

NCBI chr 6:105,121,170...105,124,036
Ensembl chr 6:105,121,170...105,124,036

G

homer scaffold protein 1

multiple interactions

Cycloserine inhibits the reaction [Clozapine results in increased expression of HOMER1 mRNA]; Cycloserine inhibits the reaction [Haloperidol results in increased expression of HOMER1 mRNA]

NCBI chr 2:24,542,777...24,645,715
Ensembl chr 2:24,543,093...24,644,785

G

mitogen activated protein kinase 1

multiple interactions

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions

Cycloserine inhibits the reaction [Dronabinol results in increased activity of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

poly (ADP-ribose) polymerase 1

multiple interactions

Cycloserine inhibits the reaction [resveratrol results in increased cleavage of PARP1 protein]

NCBI chr13:92,307,593...92,339,406
Ensembl chr13:92,307,586...92,339,404

ethambutol

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily B member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 2

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

angiotensin converting enzyme 2

increases expression

Ethambutol results in increased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

bone morphogenetic protein 6

decreases expression

Ethambutol results in decreased expression of BMP6 mRNA

NCBI chr17:26,318,121...26,469,691
Ensembl chr17:26,318,569...26,470,365

G

caspase 3

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in decreased activity of CAT protein

PMID:34118364 PMID:36878459

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine ligand 2

affects expression

Ethambutol affects the expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

affects expression

Ethambutol affects the expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cathepsin D

multiple interactions

Ethambutol results in increased expression of and affects the localization of CTSD protein; N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of and affects the localization of CTSD protein]

NCBI chr 1:197,527,467...197,539,343
Ensembl chr 1:197,527,467...197,539,488

G

cytochrome P450, family 1, subfamily a, polypeptide 2

decreases activity

Ethambutol results in decreased activity of CYP1A2 protein

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily C, polypeptide 6

decreases activity

Ethambutol results in decreased activity of CYP2C19 protein

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily d, polypeptide 4

decreases activity

Ethambutol results in decreased activity of CYP2D6 protein

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

decreases activity
increases expression
multiple interactions

Ethambutol results in decreased activity of CYP2E1 protein
Ethambutol results in increased expression of CYP2E1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Ethambutol results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

PMID:24910189 PMID:27334974 PMID:27919644

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

glutamic--pyruvic transaminase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:35835356 PMID:36878459

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

granzyme B

increases secretion

Ethambutol results in increased secretion of GZMB protein

NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

interferon gamma

increases secretion

Ethambutol results in increased secretion of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

decreases expression

Ethambutol results in decreased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 13

increases secretion

Ethambutol results in increased secretion of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 1 alpha

increases expression

Ethambutol results in increased expression of IL1A mRNA

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

decreases expression

Ethambutol results in decreased expression of IL1B mRNA

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression

Ethambutol results in decreased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

lysosomal-associated membrane protein 2

increases expression
multiple interactions

Ethambutol results in increased expression of LAMP2 protein
N,N,N',N'-tetrakis(2-pyridylmethyl)ethylenediamine inhibits the reaction [Ethambutol results in increased expression of LAMP2 protein]

NCBI chr X:117,173,097...117,222,090
Ensembl chr X:117,057,606...117,260,522

G

leptin

decreases expression

Ethambutol results in decreased expression of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

MET proto-oncogene, receptor tyrosine kinase

increases expression

Ethambutol results in increased expression of MET mRNA

NCBI chr 4:45,790,456...45,898,139
Ensembl chr 4:45,790,791...45,897,876

G

myeloperoxidase

multiple interactions

[efavirenz co-treated with Lamivudine co-treated with Tenofovir] promotes the reaction [[isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein]; [isoniazid, pyrazinamide, rifampin drug combination co-treated with Ethambutol] results in increased activity of MPO protein

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

phosphotyrosine interaction domain containing 1

increases expression

Ethambutol results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

solute carrier family 10 member 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 7 member 11

increases expression
multiple interactions

Ethambutol results in increased expression of SLC7A11 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

PMID:32816093 PMID:36878459

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

secretory leukocyte peptidase inhibitor

increases expression

Ethambutol results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

ethionamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

angiotensin converting enzyme 2

decreases expression

Ethionamide results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

C-C motif chemokine ligand 2

increases expression

Ethionamide results in increased expression of CCL2 mRNA; Ethionamide results in increased expression of CCL2 protein

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

affects expression

Ethionamide affects the expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

C-X-C motif chemokine ligand 10

decreases expression

Ethionamide results in decreased expression of CXCL10 protein

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

flavin containing dimethylaniline monoxygenase 2

increases oxidation

FMO2 protein results in increased oxidation of Ethionamide

NCBI chr13:75,221,149...75,244,377
Ensembl chr13:75,224,402...75,244,308

G

glutamate cysteine ligase, modifier subunit

multiple interactions

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of GCLM mRNA]

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

heme oxygenase 1

multiple interactions

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of HMOX1 mRNA]

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

interleukin 10

decreases expression

Ethionamide results in decreased expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12B

increases expression

Ethionamide results in increased expression of IL12B protein

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 1 alpha

increases expression

Ethionamide results in increased expression of IL1A protein

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases expression
affects expression

Ethionamide results in increased expression of IL1B mRNA
Ethionamide affects the expression of IL1B protein

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression

Ethionamide results in decreased expression of IL6 protein

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

Kelch-like ECH-associated protein 1

multiple interactions

KEAP1 mRNA inhibits the reaction [Ethionamide results in increased susceptibility to arsenic trioxide]

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

leptin

decreases expression

Ethionamide results in decreased expression of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

NFE2 like bZIP transcription factor 2

multiple interactions

NFE2L2 mRNA promotes the reaction [Ethionamide results in increased susceptibility to arsenic trioxide]

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

sulfiredoxin 1

multiple interactions

Ethionamide inhibits the reaction [arsenic trioxide results in increased expression of SRXN1 mRNA]

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

tumor necrosis factor

increases expression

Ethionamide results in increased expression of TNF protein

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

vascular endothelial growth factor A

increases expression

Ethionamide results in increased expression of VEGFA protein

NCBI chr 9:14,955,300...14,970,641
Ensembl chr 9:14,955,300...14,970,641

isoniazide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

alpha-2-macroglobulin

increases expression

Isoniazid results in increased expression of A2M mRNA

NCBI chr 4:154,897,770...154,947,787
Ensembl chr 4:154,897,877...154,947,786

G

ATP binding cassette subfamily B member 11

multiple interactions
decreases expression

[Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCB11 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCB11 mRNA]
Isoniazid results in decreased expression of ABCB11 protein
[Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein

PMID:25331106 PMID:25886055 PMID:32673658 PMID:35835356

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily C member 1

increases expression

Isoniazid results in increased expression of ABCC1 mRNA

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of ABCC2 mRNA
Isoniazid results in decreased expression of ABCC2 mRNA

PMID:25331106 PMID:32673658 PMID:35835356

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions
decreases expression

[Lipopolysaccharides co-treated with Isoniazid] results in increased expression of ABCC3 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of ABCC3 mRNA]

PMID:25331106 PMID:32673658

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 4

decreases expression

Isoniazid results in decreased expression of ABCC4 mRNA

NCBI chr15:95,541,186...95,774,898
Ensembl chr15:95,542,315...95,774,283

G

ATP binding cassette subfamily C member 6

decreases expression

Isoniazid results in decreased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

angiotensin converting enzyme 2

decreases expression

Isoniazid results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

alpha-fetoprotein

decreases expression

Isoniazid results in decreased expression of AFP mRNA

NCBI chr14:17,573,412...17,591,476
Ensembl chr14:17,573,412...17,591,480

G

1-acylglycerol-3-phosphate O-acyltransferase 3

increases expression
multiple interactions

Isoniazid results in increased expression of AGPAT3 mRNA
[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in increased expression of AGPAT3 mRNA]

NCBI chr20:10,330,960...10,415,358
Ensembl chr20:10,384,507...10,415,358

G

aldo-keto reductase family 1 member B10

increases expression

Isoniazid results in increased expression of AKR1B10 mRNA

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

5'-aminolevulinate synthase 1

increases expression

Isoniazid results in increased expression of ALAS1 protein

PMID:27438535 PMID:30517741

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

albumin

affects binding

Isoniazid binds to ALB protein

NCBI chr14:17,607,397...17,622,814
Ensembl chr14:17,607,381...17,622,836

G

alkaline phosphatase, biomineralization associated

increases activity
multiple interactions

Isoniazid results in increased activity of ALPL protein
[Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

apolipoprotein A4

affects response to substance

APOA4 affects the susceptibility to Isoniazid

NCBI chr 8:46,539,083...46,541,464
Ensembl chr 8:46,539,082...46,541,469

G

apolipoprotein A5

multiple interactions
decreases expression

[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of APOA5 mRNA]
Isoniazid results in decreased expression of APOA5 mRNA

NCBI chr 8:46,561,180...46,563,818
Ensembl chr 8:46,561,229...46,563,816

G

amyloid beta precursor protein

increases expression

Isoniazid results in increased expression of APP mRNA

NCBI chr11:24,019,774...24,236,584
Ensembl chr11:24,019,778...24,236,561

G

argininosuccinate lyase

increases activity
multiple interactions

Isoniazid results in increased activity of ASL protein
[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased activity of ASL protein]

NCBI chr12:26,659,664...26,677,136
Ensembl chr12:26,659,565...26,679,662

G

ATPase Na+/K+ transporting subunit beta 1

increases expression

Isoniazid results in increased expression of ATP1B1 mRNA

NCBI chr13:76,786,580...76,807,096
Ensembl chr13:76,786,578...76,807,459

G

ATP synthase F1 subunit beta

affects expression

Isoniazid affects the expression of ATP5F1B mRNA

NCBI chr 7:515,454...521,858
Ensembl chr 7:515,460...567,273

G

ATP synthase membrane subunit c locus 1

affects expression

Isoniazid affects the expression of ATP5MC1 mRNA

NCBI chr10:81,024,056...81,026,780
Ensembl chr10:81,023,925...81,027,124
Ensembl chr10:81,023,925...81,027,124

G

ATP synthase membrane subunit c locus 3

affects expression

Isoniazid affects the expression of ATP5MC3 mRNA

NCBI chr 3:58,810,535...58,813,185
Ensembl chr 3:58,810,535...58,814,279

G

ATP synthase peripheral stalk-membrane subunit b

affects expression

Isoniazid affects the expression of ATP5PB mRNA

NCBI chr 2:193,424,138...193,435,418
Ensembl chr 2:193,424,047...193,435,418

G

ATP synthase peripheral stalk subunit F6

affects expression

Isoniazid affects the expression of ATP5PF mRNA

NCBI chr11:23,881,594...23,889,581
Ensembl chr11:23,881,592...23,889,119

G

BCL2 associated X, apoptosis regulator

multiple interactions
increases expression
affects expression

[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
Isoniazid results in increased expression of BAX protein
Quercetin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
chrysin inhibits the reaction [Isoniazid results in increased expression of BAX protein]
Isoniazid results in increased expression of BAX mRNA
Isoniazid affects the expression of BAX protein

PMID:20433247 PMID:21419764 PMID:31332904 PMID:33121995 PMID:33771660

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

gamma-butyrobetaine hydroxylase 1

increases expression

Isoniazid results in increased expression of BBOX1 mRNA

NCBI chr 3:96,822,654...96,871,786
Ensembl chr 3:96,822,655...96,871,458

G

BCL2, apoptosis regulator

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]
Quercetin inhibits the reaction [Isoniazid results in decreased expression of BCL2 protein]
Isoniazid results in decreased expression of BCL2 mRNA

PMID:20433247 PMID:21419764 PMID:31332904 PMID:33771660

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

caspase 3

multiple interactions
increases cleavage
increases expression
increases activity

[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]
acadesine promotes the reaction [Isoniazid results in increased cleavage of CASP3 protein]; Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP3 protein]
Isoniazid results in increased expression of CASP3 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
Isoniazid results in increased activity of CASP3 protein

PMID:20433247 PMID:21419764 PMID:23764483 PMID:28556920 PMID:31332904 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 9

increases cleavage
increases activity
multiple interactions

Isoniazid results in increased cleavage of CASP9 protein
Isoniazid results in increased activity of CASP9 protein
Quercetin inhibits the reaction [Isoniazid results in increased cleavage of CASP9 protein]

PMID:20433247 PMID:31332904

NCBI chr 5:154,108,872...154,126,628
Ensembl chr 5:154,109,046...154,126,626

G

calcium-sensing receptor

affects expression

Isoniazid affects the expression of CASR mRNA

NCBI chr11:64,235,251...64,304,811
Ensembl chr11:64,235,251...64,304,811

G

catalase

decreases activity
multiple interactions

Isoniazid results in decreased activity of CAT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein; chrysin inhibits the reaction [Isoniazid results in decreased activity of CAT protein]

PMID:20433247 PMID:33121995 PMID:33771660 PMID:36878459

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

C-C motif chemokine receptor 2

decreases expression

Isoniazid results in decreased expression of CCR2 mRNA

NCBI chr 8:123,734,465...123,742,483
Ensembl chr 8:123,734,430...123,742,100

G

CCAAT/enhancer binding protein alpha

decreases expression

Isoniazid results in decreased expression of CEBPA mRNA; Isoniazid results in decreased expression of CEBPA protein

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

decreases expression

Isoniazid results in decreased expression of CEBPB protein

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein delta

decreases expression

Isoniazid results in decreased expression of CEBPD mRNA; Isoniazid results in decreased expression of CEBPD protein

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

choline phosphotransferase 1

affects response to substance

CHPT1 affects the susceptibility to Isoniazid

NCBI chr 7:22,866,455...22,915,111
Ensembl chr 7:22,863,027...22,915,103

G

claudin 2

increases expression

Isoniazid results in increased expression of CLDN2 mRNA

NCBI chr X:103,459,870...103,473,794
Ensembl chr X:103,459,780...103,474,838

G

cytochrome c oxidase copper chaperone COX11

affects expression

Isoniazid affects the expression of COX11 mRNA

NCBI chr10:75,458,735...75,465,322
Ensembl chr10:75,458,749...75,465,322

G

cytochrome c oxidase copper chaperone COX17

affects expression

Isoniazid affects the expression of COX17 mRNA

NCBI chr11:62,400,733...62,406,507

G

cytochrome c oxidase subunit 5B

affects expression

Isoniazid affects the expression of COX5B mRNA

NCBI chr 9:38,921,980...38,923,806
Ensembl chr 9:38,921,967...38,925,052

G

cytochrome c oxidase subunit 6A1

affects expression

Isoniazid affects the expression of COX6A1 mRNA

NCBI chr12:41,261,983...41,265,037
Ensembl chr12:41,261,967...41,265,041

G

cytochrome c oxidase subunit 6B1

affects expression

Isoniazid affects the expression of COX6B1 mRNA

NCBI chr 1:85,875,080...85,884,081
Ensembl chr 1:85,875,109...85,884,001
Ensembl chr 2:85,875,109...85,884,001
Ensembl chr 5:85,875,109...85,884,001

G

cytochrome c oxidase subunit 7A2

affects expression

Isoniazid affects the expression of COX7A2 mRNA

NCBI chr 8:80,716,824...80,720,922
Ensembl chr14:51,301,168...51,301,633
Ensembl chr 8:51,301,168...51,301,633

G

carnitine palmitoyltransferase 1A

affects expression

Isoniazid affects the expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

C-X-C motif chemokine ligand 10

increases secretion

Isoniazid results in increased secretion of CXCL10 protein

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

cytochrome b5 type A

multiple interactions
decreases expression

[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of CYB5A mRNA]
Isoniazid results in decreased expression of CYB5A mRNA

NCBI chr18:78,213,067...78,245,677
Ensembl chr18:78,202,342...78,258,535
Ensembl chr18:78,202,342...78,258,535

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions

[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 27, subfamily a, polypeptide 1

increases expression

Isoniazid results in increased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily c, polypeptide 79

decreases activity
multiple interactions

Isoniazid results in decreased activity of CYP2C8 protein
torsemide inhibits the reaction [Isoniazid results in decreased activity of CYP2C8 protein]

G

cytochrome P450, family 2, subfamily e, polypeptide 1

affects response to substance
increases response to substance
multiple interactions
increases activity
increases expression
increases metabolic processing

CYP2E1 gene polymorphism affects the susceptibility to Isoniazid; CYP2E1 gene SNP affects the susceptibility to Isoniazid
CYP2E1 protein results in increased susceptibility to Isoniazid
GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
Isoniazid results in increased activity of CYP2E1 protein
[Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA; Berberine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 mRNA]
Isoniazid results in increased expression of CYP2E1; Isoniazid results in increased expression of CYP2E1 mRNA; Isoniazid results in increased expression of CYP2E1 protein
2-(allylthio)pyrazine inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Isoniazid results in increased activity of CYP2E1 protein] which results in increased metabolism of 4-dichlorobenzene; [Isoniazid results in increased expression of CYP2E1] which results in increased metabolism of Acetaminophen; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Isoniazid inhibits the reaction [CYP2E1 protein results in increased reduction of tirapazamine]; Isoniazid results in increased expression of and results in increased activity of CYP2E1 protein; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]; Thiram inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]; Tiopronin inhibits the reaction [Isoniazid results in increased activity of CYP2E1 protein]
CYP2E1 protein results in increased metabolism of Isoniazid

PMID:3113478 PMID:7710944 PMID:8074729 PMID:9051121 PMID:9065729 More...

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
decreases activity
increases response to substance

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; [SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]
Isoniazid results in decreased activity of CYP3A4 protein
CYP3A4 protein results in increased susceptibility to Isoniazid

PMID:15005856 PMID:15304522 PMID:19501153 PMID:21540358 PMID:27919644

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression
increases activity
multiple interactions

Isoniazid results in increased expression of CYP3A23-3A1 mRNA
Isoniazid results in increased activity of CYP3A23-3A1 protein
diphenyleneiodonium inhibits the reaction [Isoniazid results in increased activity of CYP3A23-3A1 protein]

PMID:12883083 PMID:26880746

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
increases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased expression of CYP7A1 mRNA; obeticholic acid inhibits the reaction [Isoniazid results in increased expression of CYP7A1 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; [Isoniazid co-treated with Vitamin B 6] results in increased expression of CYP7A1 mRNA

PMID:25331106 PMID:32673658 PMID:35835356

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

DNA-damage inducible transcript 3

increases expression
decreases expression

Isoniazid results in increased expression of DDIT3 mRNA
Isoniazid results in decreased expression of DDIT3 mRNA

PMID:12883083 PMID:30008028

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

DEPP autophagy regulator 1

increases expression

Isoniazid results in increased expression of DEPP1 mRNA

NCBI chr 4:149,910,794...149,913,013
Ensembl chr 4:149,910,779...149,914,542

G

eosinophil peroxidase

increases oxidation
multiple interactions

EPX protein results in increased oxidation of Isoniazid
[EPX protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD

NCBI chr10:72,666,865...72,677,952
Ensembl chr10:72,666,865...72,677,952

G

ferrochelatase

decreases expression

Isoniazid results in decreased expression of FECH protein

PMID:27438535 PMID:30517741

NCBI chr18:57,945,123...57,978,327
Ensembl chr18:57,945,122...57,979,348

G

glucose-6-phosphate dehydrogenase

decreases activity

Isoniazid results in decreased activity of G6PD protein

NCBI chr X:152,201,081...152,220,863
Ensembl chr X:152,201,098...152,220,801

G

growth arrest and DNA-damage-inducible, alpha

decreases expression

Isoniazid results in decreased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

glyceraldehyde-3-phosphate dehydrogenase

increases expression

Isoniazid results in increased expression of GAPDH mRNA

NCBI chr 4:157,962,312...157,967,158
Ensembl chr 4:157,962,343...157,966,235

G

glutamate-cysteine ligase, catalytic subunit

multiple interactions
increases expression
decreases expression

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of GCLC mRNA]
Isoniazid results in increased expression of GCLC mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLC mRNA]
Isoniazid results in decreased expression of GCLC mRNA

PMID:24128855 PMID:33121995 PMID:33771660

NCBI chr 8:78,629,899...78,668,547
Ensembl chr 8:78,630,127...78,668,544

G

glutamate cysteine ligase, modifier subunit

decreases expression
increases expression
multiple interactions

Isoniazid results in decreased expression of GCLM mRNA
Isoniazid results in increased expression of GCLM mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of GCLM mRNA]

PMID:30008028 PMID:33121995 PMID:33771660

NCBI chr 2:210,347,482...210,367,537
Ensembl chr 2:210,347,482...210,367,535

G

glial fibrillary acidic protein

multiple interactions
increases expression

chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP mRNA]; chrysin inhibits the reaction [Isoniazid results in increased expression of GFAP protein]
Isoniazid results in increased expression of GFAP mRNA; Isoniazid results in increased expression of GFAP protein

NCBI chr10:87,852,891...87,861,631
Ensembl chr10:87,852,890...87,861,589

G

gamma-glutamyltransferase 1

multiple interactions

[Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GGT1 protein

NCBI chr20:13,074,695...13,104,095
Ensembl chr20:13,074,700...13,108,442

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases activity

[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein
Isoniazid results in increased activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

increases activity
multiple interactions
increases expression

Isoniazid results in increased activity of GPT protein
[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]
Quercetin inhibits the reaction [Isoniazid results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; [Lipopolysaccharides co-treated with Isoniazid] results in increased activity of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]; Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]; Silybin inhibits the reaction [Isoniazid promotes the reaction [Zidovudine results in increased activity of GPT protein]]

PMID:25331106 PMID:25886055 PMID:28619387 PMID:31332904 PMID:32633153 More...

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutathione S-transferase alpha 2

increases expression

Isoniazid results in increased expression of GSTA2 mRNA

NCBI chr 8:79,184,535...79,196,827
Ensembl chr 8:79,184,322...79,196,798

G

glutathione S-transferase mu 1

multiple interactions
decreases response to substance

GSTM1 protein inhibits the reaction [CYP2E1 protein results in increased susceptibility to Isoniazid]
GSTM1 protein results in decreased susceptibility to Isoniazid

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase pi 1

decreases expression

Isoniazid results in decreased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

multiple interactions

GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

PMID:18397238 PMID:20485159

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

hepatitis A virus cellular receptor 1

affects expression

Isoniazid affects the expression of HAVCR1 mRNA

NCBI chr10:31,118,667...31,151,730
Ensembl chr10:31,119,088...31,151,698

G

hepatocyte growth factor

multiple interactions

HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

heme oxygenase 1

multiple interactions
increases expression
decreases expression

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of HMOX1 mRNA]
Isoniazid results in increased expression of HMOX1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of HMOX1 mRNA]
Isoniazid results in decreased expression of HMOX1 mRNA

PMID:24128855 PMID:33121995 PMID:33771660

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

heme oxygenase 2

increases expression

Isoniazid results in increased expression of HMOX2 mRNA

NCBI chr10:10,797,076...10,831,178
Ensembl chr10:10,797,055...10,831,148

G

hypoxanthine phosphoribosyltransferase 1

increases expression

Isoniazid results in increased expression of HPRT1 mRNA

NCBI chr X:132,736,175...132,768,149
Ensembl chr X:132,736,096...132,768,154

G

interferon gamma

increases secretion

Isoniazid results in increased secretion of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

interleukin 10

increases secretion

Isoniazid results in increased secretion of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12A

increases secretion

Isoniazid results in increased secretion of IL12A protein

NCBI chr 2:152,965,769...152,973,035
Ensembl chr 2:152,965,769...152,972,734

G

interleukin 12B

increases secretion

Isoniazid results in increased secretion of IL12B protein

NCBI chr10:28,888,832...28,903,802
Ensembl chr10:28,893,008...28,902,903

G

interleukin 17A

increases secretion

Isoniazid results in increased secretion of IL17A protein

NCBI chr 9:23,144,402...23,147,889
Ensembl chr 9:23,144,402...23,147,889

G

interleukin 1 alpha

increases secretion
increases expression

Isoniazid results in increased secretion of IL1A protein
Isoniazid results in increased expression of IL1A mRNA

PMID:28444390 PMID:32816093

NCBI chr 3:116,526,601...116,537,055
Ensembl chr 3:116,526,604...116,536,822

G

interleukin 1 beta

increases secretion
multiple interactions
increases expression

Isoniazid results in increased secretion of IL1B protein
chrysin inhibits the reaction [Isoniazid results in increased expression of IL1B mRNA]

PMID:28444390 PMID:32816093 PMID:33121995

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 2

multiple interactions

[Isoniazid co-treated with Ionomycin co-treated with Tetradecanoylphorbol Acetate] results in decreased expression of IL2 mRNA

NCBI chr 2:120,004,862...120,009,566
Ensembl chr 2:120,004,862...120,009,566

G

interleukin 24

increases expression

Isoniazid results in increased expression of IL24 mRNA

NCBI chr13:42,353,089...42,358,487
Ensembl chr13:42,353,090...42,358,487

G

interleukin 6

increases expression
multiple interactions
increases secretion

Isoniazid results in increased expression of IL6 protein
Isoniazid results in increased expression of IL6 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of IL6 mRNA]
Isoniazid results in increased secretion of IL6 protein

PMID:19575532 PMID:28444390 PMID:33121995

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

inhibin subunit beta E

increases expression

Isoniazid results in increased expression of INHBE mRNA

NCBI chr 7:63,176,221...63,179,209
Ensembl chr 7:63,176,219...63,179,172

G

IZUMO1 receptor, JUNO

decreases expression

Isoniazid results in decreased expression of IZUMO1R protein

NCBI chr 8:11,744,384...11,748,131
Ensembl chr 8:11,725,863...11,748,465

G

Kelch-like ECH-associated protein 1

decreases expression

Isoniazid results in decreased expression of KEAP1 mRNA

NCBI chr 8:19,768,375...19,777,862
Ensembl chr 8:19,768,375...19,777,862

G

lysosomal-associated membrane protein 1

affects response to substance

LAMP1 affects the susceptibility to Isoniazid

NCBI chr16:76,355,982...76,380,700
Ensembl chr16:76,355,984...76,381,883

G

lipocalin 2

increases expression

Isoniazid results in increased expression of LCN2 mRNA

NCBI chr 3:15,680,688...15,684,033
Ensembl chr 3:15,680,687...15,684,095

G

microtubule-associated protein 2

affects expression

Isoniazid affects the expression of MAP2 mRNA

NCBI chr 9:67,723,422...67,981,886
Ensembl chr 9:67,723,371...67,979,809

G

mitogen activated protein kinase 1

decreases phosphorylation
multiple interactions

Isoniazid results in decreased phosphorylation of MAPK1 protein
6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK1 protein]

NCBI chr11:83,957,813...84,023,629
Ensembl chr11:83,957,813...84,023,616

G

mitogen activated protein kinase 3

multiple interactions
decreases phosphorylation

6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide inhibits the reaction [Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]]; Quercetin inhibits the reaction [Isoniazid results in decreased phosphorylation of MAPK3 protein]

NCBI chr 1:181,366,646...181,372,863
Ensembl chr 1:181,366,637...181,372,863

G

microsomal glutathione S-transferase 1

increases expression

Isoniazid results in increased expression of MGST1 mRNA

NCBI chr 4:171,029,666...171,044,893
Ensembl chr 4:171,029,630...171,044,892

G

microRNA 106b

decreases expression

Isoniazide decreased expression of miR106b miRNA in the liver

RGD

NCBI chr12:17,043,344...17,043,425
Ensembl chr12:17,043,344...17,043,425

G

microRNA 186

multiple interactions

[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA

NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:246,582,806...246,582,891

G

myeloperoxidase

multiple interactions
increases oxidation

[[MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals] which results in increased chemical synthesis of isonicotinyl-NAD; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of Free Radicals; [MPO protein results in increased oxidation of Isoniazid] which results in increased chemical synthesis of isonicotinyl-NAD

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

mitochondrially encoded cytochrome c oxidase III

increases expression

Isoniazid results in increased expression of COX3 mRNA

NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
NCBI chr MT:8,599...9,382
Ensembl chr MT:8,599...9,382

G

mucin 1, cell surface associated

increases expression

Isoniazid results in increased expression of MUC1 mRNA

NCBI chr 2:174,635,989...174,640,738
Ensembl chr 2:174,635,995...174,640,733

G

N-acetyltransferase 2

increases acetylation
affects acetylation
multiple interactions
decreases expression
decreases acetylation
increases metabolic processing
affects metabolic processing
affects response to substance

NAT2 protein polymorphism results in increased acetylation of Isoniazid; NAT2 protein results in increased acetylation of Isoniazid
NAT2 protein polymorphism affects the acetylation of Isoniazid
[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of NAT2 mRNA]
Isoniazid results in decreased expression of NAT2 mRNA
[NAT2 gene polymorphism results in decreased acetylation of Isoniazid] which results in decreased abundance of acetylisoniazid; [NAT2 gene polymorphism results in decreased metabolism of Isoniazid] which results in increased abundance of hydrazine
NAT2 protein results in increased metabolism of Isoniazid
NAT2 protein affects the metabolism of Isoniazid; NAT2 protein polymorphism affects the metabolism of Isoniazid
NAT2 gene polymorphism affects the susceptibility to Isoniazid; NAT2 gene SNP affects the susceptibility to Isoniazid

PMID:11379777 PMID:11915035 PMID:15546075 PMID:15565348 PMID:15618686 More...

NCBI chr16:22,207,362...22,238,513
Ensembl chr16:22,208,194...22,238,520

G

natural killer cell cytotoxicity receptor 3 ligand 1

increases expression

Isoniazid results in increased expression of NCR3LG1 mRNA; Isoniazid results in increased expression of NCR3LG1 protein

NCBI chr 1:96,565,664...96,581,825
Ensembl chr 1:96,574,455...96,580,466

G

NADH:ubiquinone oxidoreductase subunit A1

affects expression

Isoniazid affects the expression of NDUFA1 mRNA

NCBI chr X:116,424,223...116,427,875
Ensembl chr X:116,424,223...116,428,633

G

NADH:ubiquinone oxidoreductase subunit A10

affects expression

Isoniazid affects the expression of NDUFA10 mRNA

NCBI chr 9:93,007,034...93,041,825
Ensembl chr 9:93,007,042...93,042,560

G

NADH:ubiquinone oxidoreductase subunit A12

affects expression

Isoniazid affects the expression of NDUFA12 mRNA

NCBI chr 7:28,771,330...28,798,316
Ensembl chr 7:28,771,330...28,798,315

G

NADH:ubiquinone oxidoreductase subunit A13

affects expression

Isoniazid affects the expression of NDUFA13 mRNA

NCBI chr16:19,526,633...19,533,567
Ensembl chr16:19,526,565...19,535,726
Ensembl chr 7:19,526,565...19,535,726

G

Ndufa4, mitochondrial complex associated

affects expression

Isoniazid affects the expression of NDUFA4 mRNA

NCBI chr 4:40,002,216...40,009,384
Ensembl chr 4:40,002,216...40,023,920

G

NADH:ubiquinone oxidoreductase subunit A5

affects expression

Isoniazid affects the expression of NDUFA5 mRNA

NCBI chr 4:52,997,327...53,005,685
Ensembl chr 4:52,995,546...53,005,598
Ensembl chr 5:52,995,546...53,005,598

G

NADH:ubiquinone oxidoreductase subunit A8

affects expression

Isoniazid affects the expression of NDUFA8 mRNA

NCBI chr 3:19,386,062...19,402,090
Ensembl chr 3:19,386,065...19,402,071

G

NADH:ubiquinone oxidoreductase subunit A9

affects expression

Isoniazid affects the expression of NDUFA9 mRNA

NCBI chr 4:159,659,242...159,688,034
Ensembl chr 4:159,659,242...159,688,018

G

NADH:ubiquinone oxidoreductase subunit AB1

affects expression

Isoniazid affects the expression of NDUFAB1 mRNA

NCBI chr 1:176,644,696...176,658,131
Ensembl chr 1:176,644,703...176,658,099

G

NADH:ubiquinone oxidoreductase subunit B10

affects expression

Isoniazid affects the expression of NDUFB10 mRNA

NCBI chr10:13,749,273...13,751,434
Ensembl chr10:13,749,275...13,751,442

G

NADH:ubiquinone oxidoreductase subunit B2

affects expression

Isoniazid affects the expression of NDUFB2 mRNA

NCBI chr 4:68,367,526...68,374,609
Ensembl chr15:46,536,062...46,536,851
Ensembl chr 4:46,536,062...46,536,851

G

NADH:ubiquinone oxidoreductase subunit B3

affects expression

Isoniazid affects the expression of NDUFB3 mRNA

NCBI chr 9:60,129,240...60,139,452
Ensembl chr 9:60,129,154...60,139,446

G

NADH:ubiquinone oxidoreductase subunit B5

affects expression

Isoniazid affects the expression of NDUFB5 mRNA

NCBI chr 2:115,519,248...115,533,589
Ensembl chr 2:115,519,154...115,533,589

G

NADH:ubiquinone oxidoreductase subunit B6

affects expression

Isoniazid affects the expression of NDUFB6 mRNA

NCBI chr 5:55,400,543...55,410,110
Ensembl chr 5:55,400,543...55,410,181

G

NADH:ubiquinone oxidoreductase subunit B7

affects expression

Isoniazid affects the expression of NDUFB7 mRNA

NCBI chr19:24,568,241...24,572,579
Ensembl chr19:24,568,241...24,572,579

G

NADH:ubiquinone oxidoreductase core subunit S1

affects expression

Isoniazid affects the expression of NDUFS1 mRNA

NCBI chr 9:64,546,430...64,579,751
Ensembl chr 9:64,546,225...64,579,893

G

NADH:ubiquinone oxidoreductase core subunit S2

affects expression

Isoniazid affects the expression of NDUFS2 mRNA

NCBI chr13:83,654,402...83,671,474
Ensembl chr13:83,654,406...83,671,420

G

NADH:ubiquinone oxidoreductase core subunit S3

affects expression

Isoniazid affects the expression of NDUFS3 mRNA

NCBI chr 3:76,876,646...76,883,824
Ensembl chr 3:76,876,646...76,883,824

G

NADH:ubiquinone oxidoreductase subunit S4

affects expression

Isoniazid affects the expression of NDUFS4 mRNA

NCBI chr 2:45,951,327...46,061,829
Ensembl chr 2:45,951,313...46,061,846

G

NADH:ubiquinone oxidoreductase core subunit S8

affects expression

Isoniazid affects the expression of NDUFS8 mRNA

NCBI chr 1:201,140,585...201,144,573
Ensembl chr 1:201,140,585...201,144,511

G

NADH:ubiquinone oxidoreductase core subunit V1

affects expression

Isoniazid affects the expression of NDUFV1 mRNA

NCBI chr 1:201,300,365...201,305,461
Ensembl chr 1:201,299,985...201,305,466

G

NADH:ubiquinone oxidoreductase core subunit V2

affects expression

Isoniazid affects the expression of NDUFV2 mRNA

NCBI chr 9:105,690,454...105,710,669
Ensembl chr 9:105,690,455...105,710,713

G

NFE2 like bZIP transcription factor 2

increases activity
increases expression
multiple interactions

Isoniazid results in increased activity of NFE2L2 protein
Isoniazid results in increased expression of NFE2L2 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NFE2L2 mRNA]

PMID:30203046 PMID:33121995 PMID:33771660

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear factor kappa B subunit 1

increases expression
multiple interactions

Isoniazid results in increased expression of NFKB1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NFKB1 mRNA]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:224,016,214...224,110,404

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression
decreases expression

Isoniazid inhibits the reaction [2-tert-butylhydroquinone results in increased expression of NQO1 mRNA]
Isoniazid results in increased expression of NQO1 mRNA
chrysin inhibits the reaction [Isoniazid results in increased expression of NQO1 mRNA]
Isoniazid results in decreased expression of NQO1 mRNA

PMID:24128855 PMID:28444390 PMID:33121995 PMID:33771660

NCBI chr19:35,295,633...35,310,528
Ensembl chr19:35,295,573...35,310,557

G

nuclear receptor subfamily 0, group B, member 2

decreases expression
multiple interactions

Isoniazid results in decreased expression of NR0B2 mRNA
[Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR0B2 mRNA
obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR0B2 mRNA]

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 mRNA; [Lipopolysaccharides co-treated with Isoniazid] results in decreased expression of NR1H4 protein; obeticholic acid inhibits the reaction [Isoniazid results in decreased expression of NR1H4 mRNA]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; [Isoniazid co-treated with Vitamin B 6] results in decreased expression of NR1H4 mRNA
isoniazide decreases expression of nr1h4 protein in rat liver

CTD
RGD

PMID:25331106 PMID:32673658 PMID:35835356 PMID:30068870

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

nuclear receptor subfamily 1, group I, member 3

increases activity

Isoniazid results in increased activity of NR1I3 protein

NCBI chr13:83,632,940...83,638,193
Ensembl chr13:83,632,899...83,637,906

G

nuclear respiratory factor 1

multiple interactions
decreases expression

acadesine inhibits the reaction [Isoniazid results in decreased expression of NRF1 protein]

NCBI chr 4:58,664,932...58,772,328
Ensembl chr 4:58,664,957...58,825,328

G

nuclear protein 1, transcriptional regulator

increases expression

Isoniazid results in increased expression of NUPR1 mRNA

NCBI chr 1:181,213,292...181,215,327
Ensembl chr 1:181,213,368...181,215,281

G

oxoglutarate dehydrogenase

affects expression

Isoniazid affects the expression of OGDH mRNA

NCBI chr14:81,150,021...81,217,479
Ensembl chr14:81,150,091...81,217,479

G

Parkinsonism associated deglycase

affects expression

Isoniazid affects the expression of PARK7 mRNA

NCBI chr 5:161,353,718...161,376,993
Ensembl chr 5:161,353,719...161,376,970

G

phosphotyrosine interaction domain containing 1

increases expression

Isoniazid results in increased expression of PID1 mRNA

NCBI chr 9:85,284,335...85,503,035
Ensembl chr 9:85,284,335...85,503,044

G

procollagen lysine, 2-oxoglutarate 5-dioxygenase 2

increases expression

Isoniazid results in increased expression of PLOD2 mRNA

NCBI chr 8:93,084,548...93,167,255
Ensembl chr 8:93,084,513...93,167,255

G

cytochrome p450 oxidoreductase

multiple interactions
decreases expression

[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA; silybin inhibits the reaction [[Zidovudine co-treated with Isoniazid] results in decreased expression of POR mRNA]
Isoniazid results in decreased expression of POR mRNA

NCBI chr12:20,951,058...20,999,198
Ensembl chr12:20,951,058...20,999,245

G

peroxisome proliferator activated receptor alpha

increases activity
multiple interactions

Isoniazid results in increased activity of PPARA protein
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARA protein

PMID:30203046 PMID:36347327

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

peroxisome proliferator-activated receptor gamma

decreases expression
multiple interactions

Isoniazid results in decreased expression of PPARG mRNA
[Isoniazid co-treated with Rifampin] results in decreased expression of PPARG protein
Isoniazid results in decreased expression of PPARG mRNA; Isoniazid results in decreased expression of PPARG protein

PMID:24128855 PMID:36347327

NCBI chr 4:148,423,102...148,548,471
Ensembl chr 4:148,423,194...148,548,468

G

PPARG coactivator 1 alpha

decreases expression
multiple interactions

Isoniazid results in decreased expression of PPARGC1A protein
acadesine inhibits the reaction [Isoniazid results in decreased expression of PPARGC1A protein]

NCBI chr14:58,860,752...59,516,525
Ensembl chr14:58,861,144...59,512,656

G

presenilin 1

affects expression

Isoniazid affects the expression of PSEN1 mRNA

NCBI chr 6:103,323,052...103,375,088
Ensembl chr 6:103,323,120...103,371,650

G

prostaglandin-endoperoxide synthase 2

increases expression

Isoniazid results in increased expression of PTGS2 mRNA

NCBI chr13:62,163,936...62,172,193
Ensembl chr13:62,163,932...62,172,188

G

succinate dehydrogenase complex flavoprotein subunit A

affects expression

Isoniazid affects the expression of SDHA mRNA

NCBI chr 1:28,935,965...28,960,936
Ensembl chr 1:28,940,164...28,961,535

G

succinate dehydrogenase complex iron sulfur subunit B

affects expression

Isoniazid affects the expression of SDHB mRNA

NCBI chr 5:153,264,906...153,285,570
Ensembl chr 5:153,264,899...153,314,293

G

succinate dehydrogenase complex subunit D

affects expression

Isoniazid affects the expression of SDHD mRNA

NCBI chr 8:50,944,702...50,954,298
Ensembl chr 8:50,944,704...50,954,238

G

stratifin

decreases expression

Isoniazid results in decreased expression of SFN mRNA

NCBI chr 5:145,826,722...145,827,994
Ensembl chr 5:145,826,201...145,831,314

G

sirtuin 1

multiple interactions
decreases expression

acadesine inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]; Quercetin inhibits the reaction [Isoniazid results in decreased expression of SIRT1 protein]

PMID:28556920 PMID:31332904

NCBI chr20:25,307,225...25,329,273
Ensembl chr20:25,306,917...25,329,260

G

solute carrier family 10 member 1

decreases expression
multiple interactions

Isoniazid results in decreased expression of SLC10A1 mRNA
Isoniazid results in decreased expression of SLC10A1 protein
[Rifampin co-treated with Isoniazid] results in decreased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1
obeticholic acid promotes the reaction [Isoniazid results in decreased expression of SLC10A1 mRNA]

PMID:25886055 PMID:32673658 PMID:35835356

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 11 member 1

affects expression

Isoniazid affects the expression of SLC11A1 mRNA

NCBI chr 9:75,957,193...75,968,115
Ensembl chr 9:75,957,316...75,968,101

G

solute carrier family 7 member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier family 7 member 5

decreases expression

Isoniazid results in decreased expression of SLC7A5 mRNA

NCBI chr19:49,935,220...49,963,823
Ensembl chr19:49,935,220...49,963,823

G

solute carrier organic anion transporter family, member 1c1

decreases expression

Isoniazid results in decreased expression of SLCO1B1 mRNA

NCBI chr 4:174,466,621...174,513,290
Ensembl chr 4:174,466,631...174,513,289

G

secretory leukocyte peptidase inhibitor

increases expression

Isoniazid results in increased expression of SLPI mRNA

NCBI chr 3:153,082,208...153,084,457
Ensembl chr 3:153,082,369...153,084,453

G

superoxide dismutase 1

increases expression

Isoniazid results in increased expression of SOD1 mRNA

NCBI chr11:29,456,673...29,462,249
Ensembl chr11:29,456,558...29,462,249

G

superoxide dismutase 2

multiple interactions
affects expression

[SOD2 co-treated with CYP3A4] affects the susceptibility to Isoniazid
Isoniazid affects the expression of SOD2 mRNA

PMID:19501153 PMID:24848797

NCBI chr 1:47,638,318...47,645,163
Ensembl chr 1:47,636,528...47,645,189

G

secreted phosphoprotein 1

affects expression
decreases expression

Isoniazid affects the expression of SPP1 mRNA
Isoniazid results in decreased expression of SPP1 mRNA

PMID:20623750 PMID:30008028

NCBI chr14:5,308,885...5,315,120
Ensembl chr14:5,308,885...5,315,162

G

sulfiredoxin 1

increases expression

Isoniazid results in increased expression of SRXN1 mRNA

NCBI chr 3:140,604,490...140,610,050
Ensembl chr 3:140,599,608...140,628,448

G

SURF1, cytochrome c oxidase assembly factor

affects expression

Isoniazid affects the expression of SURF1 mRNA

NCBI chr 3:10,241,793...10,244,686
Ensembl chr 3:10,241,837...10,263,315

G

transferrin

increases expression

Isoniazid results in increased expression of TF mRNA

NCBI chr 8:103,789,780...103,816,487
Ensembl chr 8:103,767,995...103,816,511

G

tumor necrosis factor

increases expression
multiple interactions
increases secretion

Isoniazid results in increased expression of TNF protein
[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein; chrysin inhibits the reaction [Isoniazid results in increased expression of TNF protein]; Isoniazid promotes the reaction [Lipopolysaccharides results in increased expression of TNF protein]; Silybin inhibits the reaction [[Isoniazid co-treated with Zidovudine] results in increased expression of TNF protein]
Isoniazid results in increased secretion of TNF protein

PMID:25331106 PMID:28444390 PMID:28619387 PMID:33121995

NCBI chr20:3,622,011...3,624,629
Ensembl chr20:3,622,011...3,624,629

G

thyroid peroxidase

decreases activity

Isoniazid results in decreased activity of TPO protein

NCBI chr 6:46,698,402...46,768,199
Ensembl chr 6:46,698,414...46,768,199

G

trafficking kinesin protein 1

affects expression

Isoniazid affects the expression of TRAK1 mRNA

NCBI chr 8:120,984,445...121,139,357
Ensembl chr 8:120,984,431...121,139,367

G

tribbles pseudokinase 3

increases expression

Isoniazid results in increased expression of TRIB3 mRNA

NCBI chr 3:140,809,634...140,815,230
Ensembl chr 3:140,809,043...140,814,497

G

thioredoxin 2

affects expression

Isoniazid affects the expression of TXN2 mRNA

NCBI chr 7:109,496,772...109,510,378
Ensembl chr 7:109,496,761...109,510,359

G

thioredoxin reductase 1

increases expression

Isoniazid results in increased expression of TXNRD1 mRNA

NCBI chr 7:20,830,042...20,914,990
Ensembl chr 7:20,830,045...20,907,863

G

thioredoxin reductase 2

affects expression

Isoniazid affects the expression of TXNRD2 mRNA

NCBI chr11:82,519,996...82,568,156
Ensembl chr11:82,519,999...82,568,156

G

ubiquinol-cytochrome c reductase binding protein

affects expression

Isoniazid affects the expression of UQCRB mRNA

NCBI chr 7:63,814,784...63,820,150
Ensembl chr 7:63,814,797...63,820,150

G

ubiquinol cytochrome c reductase core protein 2

affects expression

Isoniazid affects the expression of UQCRC2 mRNA

NCBI chr 1:175,167,933...175,198,499
Ensembl chr 1:175,167,894...175,199,453

lomefloxacin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

potassium voltage-gated channel subfamily H member 2

affects binding

lomefloxacin binds to KCNH2 protein

NCBI chr 4:10,826,834...10,859,009
Ensembl chr 4:10,826,928...10,859,008

G

matrix metallopeptidase 2

increases expression
increases activity

lomefloxacin results in increased expression of MMP2 mRNA
lomefloxacin results in increased activity of MMP2 protein

NCBI chr19:14,154,657...14,182,870
Ensembl chr19:14,154,657...14,182,870

G

matrix metallopeptidase 9

increases expression
increases activity

lomefloxacin results in increased expression of MMP9 mRNA
lomefloxacin results in increased activity of MMP9 protein

NCBI chr 3:153,684,158...153,692,118
Ensembl chr 3:153,683,858...153,692,120

N'-acetylisoniazid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

myeloperoxidase

increases oxidation

MPO protein results in increased oxidation of (N)1-acetylisoniazid

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

pyrazine-2-carboxylic acid

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

aminocarboxymuconate semialdehyde decarboxylase

decreases activity

pyrazinoic acid metabolite results in decreased activity of ACMSD protein

NCBI chr13:39,200,412...39,245,954
Ensembl chr13:39,200,314...39,245,209

G

catalase

decreases expression

pyrazinoic acid results in decreased expression of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

glutamic--pyruvic transaminase

increases activity

pyrazinoic acid results in increased activity of GPT protein

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

solute carrier family 22 member 12

multiple interactions

pyrazinoic acid promotes the reaction [SLC22A12 protein affects the transport of Uric Acid]

PMID:14747372 PMID:21074513

NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555

G

solute carrier family 22 member 6

multiple interactions

pyrazinoic acid inhibits the reaction [SLC22A6 protein affects the transport of Uric Acid]

NCBI chr 1:205,522,579...205,531,179
Ensembl chr 1:205,522,729...205,531,173

pyrazinecarboxamide

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily A member 1

increases expression

Pyrazinamide results in increased expression of ABCA1 mRNA

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 3

decreases expression

Pyrazinamide results in decreased expression of ABCA3 mRNA

NCBI chr10:13,382,439...13,439,748
Ensembl chr10:13,382,540...13,439,745

G

ATP binding cassette subfamily B member 11

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of ABCB11 mRNA; Pyrazinamide results in decreased expression of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB11 mRNA]

PMID:27255380 PMID:35835356

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 4

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCB4 mRNA]
Pyrazinamide results in decreased expression of ABCB4 mRNA; Pyrazinamide results in decreased expression of ABCB4 protein

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 6

increases expression

Pyrazinamide results in increased expression of ABCB6 mRNA

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

ATP binding cassette subfamily C member 2

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of ABCC2 mRNA]
Pyrazinamide results in decreased expression of ABCC2 mRNA; Pyrazinamide results in decreased expression of ABCC2 protein

PMID:27255380 PMID:35835356

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

increases expression

Pyrazinamide results in increased expression of ABCC3 mRNA; Pyrazinamide results in increased expression of ABCC3 protein

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP-binding cassette, subfamily G (WHITE), member 3-like 1

decreases expression

Pyrazinamide results in decreased expression of ABCG3L1 mRNA

NCBI chr14:5,124,541...5,177,265
Ensembl chr14:5,124,353...5,177,184

G

acetyl-CoA acyltransferase 1A

increases expression
multiple interactions

Pyrazinamide results in increased expression of ACAA1 mRNA
Fenofibrate promotes the reaction [Pyrazinamide results in increased expression of ACAA1 mRNA]; Pyrazinamide promotes the reaction [Fenofibrate results in increased expression of ACAA1 mRNA]

PMID:22431067 PMID:27071702

NCBI chr 8:119,079,401...119,088,626
Ensembl chr 8:119,079,775...119,088,624

G

acetyl-Coenzyme A acyltransferase 1B

increases expression

Pyrazinamide results in increased expression of ACAA1B mRNA

NCBI chr 8:118,872,996...118,881,852
Ensembl chr 8:118,872,997...118,881,825

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

acyl-CoA synthetase medium-chain family member 2

increases expression

Pyrazinamide results in increased expression of ACSM2 mRNA

NCBI chr 1:173,916,368...173,955,116
Ensembl chr 1:173,916,368...173,955,116

G

aldo-keto reductase family 7 member A3

increases expression

Pyrazinamide results in increased expression of AKR7A3 mRNA

NCBI chr 5:151,590,968...151,601,394
Ensembl chr 5:151,584,479...151,601,394

G

aldehyde dehydrogenase 1 family, member A1

increases expression

Pyrazinamide results in increased expression of ALDH1A1 mRNA

NCBI chr 1:218,000,470...218,152,962
Ensembl chr 1:218,042,127...218,152,961

G

aldehyde dehydrogenase 1 family, member L1

increases expression

Pyrazinamide results in increased expression of ALDH1L1 mRNA

NCBI chr 4:123,059,989...123,106,471
Ensembl chr 4:123,060,008...123,106,465

G

alkB homolog 2, alpha-ketoglutarate-dependent dioxygenase

decreases expression

Pyrazinamide results in decreased expression of ALKBH2 mRNA

NCBI chr12:42,494,187...42,500,929
Ensembl chr12:42,496,300...42,500,914

G

apolipoprotein A1

multiple interactions
increases expression

[Fenofibrate co-treated with Pyrazinamide] results in increased expression of APOA1 mRNA
Pyrazinamide results in increased expression of APOA1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 8:46,527,251...46,529,035
Ensembl chr 8:46,527,144...46,529,035

G

asparagine synthetase (glutamine-hydrolyzing)

increases expression

Pyrazinamide results in increased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:35,785,237...35,803,423

G

activating transcription factor 3

increases expression

Pyrazinamide results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of ATF4 protein]
Pyrazinamide results in increased expression of ATF4 mRNA; Pyrazinamide results in increased expression of ATF4 protein

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression

Pyrazinamide results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

Bcl2-like 10

decreases expression

Pyrazinamide results in decreased expression of BCL2L10 mRNA

NCBI chr 8:76,107,326...76,113,373
Ensembl chr 8:76,107,326...76,113,367

G

Bcl2-like 2

decreases expression

Pyrazinamide results in decreased expression of BCL2L2 mRNA

NCBI chr15:28,346,449...28,361,627
Ensembl chr15:28,356,807...28,361,624

G

BAF chromatin remodeling complex subunit BCL7C

increases expression

Pyrazinamide results in increased expression of BCL7C mRNA

NCBI chr 1:182,277,163...182,324,274
Ensembl chr 1:182,260,164...182,324,163

G

Bcl2 modifying factor

decreases expression

Pyrazinamide results in decreased expression of BMF mRNA

NCBI chr 3:105,499,534...105,520,159
Ensembl chr 3:105,499,538...105,520,145

G

caspase 3

increases cleavage
multiple interactions

Pyrazinamide results in increased cleavage of CASP3 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3

PMID:28063906 PMID:35835356

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

catalase

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of CAT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

PMID:28425350 PMID:36878459

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

cell division cycle and apoptosis regulator 1

decreases expression

Pyrazinamide results in decreased expression of CCAR1 mRNA

NCBI chr20:30,685,916...30,728,531
Ensembl chr20:30,685,916...30,728,526

G

cyclin E2

decreases expression

Pyrazinamide results in decreased expression of CCNE2 mRNA

NCBI chr 5:24,285,078...24,298,258
Ensembl chr 5:24,284,922...24,297,632

G

cyclin-dependent kinase 20

decreases expression

Pyrazinamide results in decreased expression of CDK20 mRNA

NCBI chr17:701,122...707,869
Ensembl chr17:701,124...707,826

G

cyclin-dependent kinase 4

increases expression

Pyrazinamide results in increased expression of CDK4 mRNA

NCBI chr 7:62,886,124...62,889,562
Ensembl chr 7:62,883,105...62,942,403

G

cyclin dependent kinase inhibitor 2D

increases expression

Pyrazinamide results in increased expression of CDKN2D mRNA

NCBI chr 8:19,831,874...19,834,640
Ensembl chr 8:19,831,866...19,834,674

G

CCAAT/enhancer binding protein beta

increases expression

Pyrazinamide results in increased expression of CEBPB mRNA

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein delta

increases expression

Pyrazinamide results in increased expression of CEBPD mRNA

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

collagen type I alpha 1 chain

increases expression

Pyrazinamide results in increased expression of COL1A1 mRNA

NCBI chr10:79,883,622...79,900,625
Ensembl chr10:79,883,622...79,900,624

G

carnitine palmitoyltransferase 1B

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of CPT1B mRNA
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of CPT1B mRNA]

PMID:22431067 PMID:27071702

NCBI chr 7:120,491,354...120,500,833
Ensembl chr 7:120,491,354...120,500,404

G

cytochrome P450, family 1, subfamily a, polypeptide 2

increases expression

Pyrazinamide results in increased expression of CYP1A2 mRNA

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 2, subfamily b, polypeptide 1

increases expression

Pyrazinamide results in increased expression of CYP2B1 mRNA

NCBI chr 1:81,518,387...81,544,999
Ensembl chr 1:81,518,408...81,542,052

G

cytochrome P450, family 2, subfamily b, polypeptide 2

increases expression

Pyrazinamide results in increased expression of CYP2B2 mRNA

NCBI chr 1:81,594,534...81,608,567
Ensembl chr 1:81,594,555...81,608,566

G

cytochrome P450, family 2, subfamily b, polypeptide 21

increases expression

Pyrazinamide results in increased expression of CYP2B21 mRNA

NCBI chr 1:81,886,097...81,915,066
Ensembl chr 1:81,886,098...81,915,066

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression

Pyrazinamide results in increased expression of CYP2D4 mRNA

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily d, polypeptide 5

increases expression

Pyrazinamide results in increased expression of CYP2D5 mRNA

NCBI chr 7:113,899,905...113,904,458
Ensembl chr 7:113,899,890...113,904,495

G

cytochrome P450, family 2, subfamily e, polypeptide 1

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily j, polypeptide 3

decreases expression

Pyrazinamide results in decreased expression of CYP2J3 mRNA

NCBI chr 5:111,219,921...111,244,987
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

increases expression

Pyrazinamide results in increased expression of CYP3A23-3A1 mRNA

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

decreases expression

Pyrazinamide results in decreased expression of CYP3A9 mRNA

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450, family 51

increases expression

Pyrazinamide results in increased expression of CYP51 mRNA

NCBI chr 4:30,036,956...30,055,410
Ensembl chr 4:30,036,865...30,055,410
Ensembl chr 6:30,036,865...30,055,410

G

cytochrome P450 family 7 subfamily A member 1

increases expression
multiple interactions

Pyrazinamide results in increased expression of CYP7A1 mRNA; Pyrazinamide results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein

PMID:27255380 PMID:35835356

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

decreases expression
increases expression

Pyrazinamide results in decreased expression of CYP8B1 mRNA; Pyrazinamide results in decreased expression of CYP8B1 protein
Pyrazinamide results in increased expression of CYP8B1 mRNA

PMID:22431067 PMID:27255380

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of DDIT3 protein]
Pyrazinamide results in increased expression of DDIT3 mRNA; Pyrazinamide results in increased expression of DDIT3 protein

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

dual specificity tyrosine phosphorylation regulated kinase 2

decreases expression

Pyrazinamide results in decreased expression of DYRK2 mRNA

NCBI chr 7:54,348,724...54,381,363
Ensembl chr 7:54,349,610...54,380,106

G

eukaryotic translation initiation factor 2 alpha kinase 3

multiple interactions
increases phosphorylation

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2AK3 protein]

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation
multiple interactions

Pyrazinamide results in increased phosphorylation of EIF2S1 protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased phosphorylation of EIF2S1 protein]

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

E1A binding protein p300

decreases expression

Pyrazinamide results in decreased expression of EP300 mRNA

NCBI chr 7:113,108,476...113,178,529
Ensembl chr 7:113,106,247...113,136,088
Ensembl chr 7:113,106,247...113,136,088

G

epoxide hydrolase 1

increases expression

Pyrazinamide results in increased expression of EPHX1 mRNA

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

ERCC excision repair 1, endonuclease non-catalytic subunit

increases expression

Pyrazinamide results in increased expression of ERCC1 mRNA

NCBI chr 1:78,971,310...79,007,963
Ensembl chr 1:78,996,390...79,007,963

G

endoplasmic reticulum to nucleus signaling 1

increases expression

Pyrazinamide results in increased expression of ERN1 mRNA

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

fatty acid binding protein 1

multiple interactions
decreases expression

Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of FABP1 mRNA]

NCBI chr 4:103,191,015...103,194,791
Ensembl chr 4:103,191,006...103,194,788

G

fatty acid binding protein 7

decreases expression

Pyrazinamide results in decreased expression of FABP7 mRNA

NCBI chr20:37,123,193...37,126,725
Ensembl chr20:37,123,193...37,126,880

G

F-box and WD repeat domain containing 11

decreases expression

Pyrazinamide results in decreased expression of FBXW11 mRNA

NCBI chr10:17,232,735...17,330,574
Ensembl chr10:17,227,181...17,330,571

G

flavin containing dimethylaniline monoxygenase 1

increases expression

Pyrazinamide results in increased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

growth arrest and DNA-damage-inducible, alpha

increases expression

Pyrazinamide results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest-specific 2

increases expression

Pyrazinamide results in increased expression of GAS2 mRNA

NCBI chr 1:101,452,361...101,582,619
Ensembl chr 1:101,482,591...101,582,619

G

glutamic--pyruvic transaminase

increases expression
increases activity
multiple interactions

Pyrazinamide results in increased expression of GPT protein
Pyrazinamide results in increased activity of GPT protein
4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; Fenofibrate inhibits the reaction [Pyrazinamide results in increased expression of GPT protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:27071702 PMID:28063906 PMID:28425350 PMID:35835356 PMID:36878459

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutathione S-transferase alpha 4

increases expression

Pyrazinamide results in increased expression of GSTA4 mRNA

NCBI chr 8:79,066,967...79,084,193
Ensembl chr 8:79,066,934...79,084,182

G

glutathione S-transferase alpha 5

increases expression

Pyrazinamide results in increased expression of GSTA5 mRNA

NCBI chr 8:79,105,561...79,117,472
Ensembl chr 8:79,105,661...79,117,472

G

glutathione S-transferase mu 1

increases expression

Pyrazinamide results in increased expression of GSTM1 mRNA

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase mu 2

increases expression

Pyrazinamide results in increased expression of GSTM2 mRNA

NCBI chr 2:195,624,015...195,628,774
Ensembl chr 2:195,544,426...195,628,961

G

glutathione S-transferase pi 1

increases expression

Pyrazinamide results in increased expression of GSTP1 mRNA

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

multiple interactions

GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

3-hydroxy-3-methylglutaryl-CoA synthase 1

increases expression

Pyrazinamide results in increased expression of HMGCS1 mRNA

NCBI chr 2:51,649,368...51,667,100
Ensembl chr 2:51,649,497...51,667,100

G

3-hydroxy-3-methylglutaryl-CoA synthase 2

increases expression

Pyrazinamide results in increased expression of HMGCS2 mRNA

NCBI chr 2:185,875,609...185,903,505
Ensembl chr 2:185,875,616...185,902,130

G

heme oxygenase 1

increases expression

Pyrazinamide results in increased expression of HMOX1 mRNA

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hydroxysteroid 11-beta dehydrogenase 1

increases expression

Pyrazinamide results in increased expression of HSD11B1 mRNA

NCBI chr13:104,728,539...104,798,884
Ensembl chr13:104,728,539...104,788,687

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

4-phenylbutyric acid inhibits the reaction [Pyrazinamide results in increased expression of HSPA5 protein]
Pyrazinamide results in increased expression of HSPA5 mRNA; Pyrazinamide results in increased expression of HSPA5 protein

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

inositol 1,4,5-trisphosphate receptor, type 1

decreases expression

Pyrazinamide results in decreased expression of ITPR1 mRNA

NCBI chr 4:141,187,377...141,554,240
Ensembl chr 4:141,187,418...141,510,491

G

lipoprotein lipase

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of LPL mRNA
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of LPL mRNA]

NCBI chr16:20,830,055...20,853,855
Ensembl chr16:20,829,465...20,855,249

G

malic enzyme 1

increases expression

Pyrazinamide results in increased expression of ME1 mRNA

PMID:22431067 PMID:27071702

NCBI chr 8:87,549,043...87,660,251
Ensembl chr 8:87,549,043...87,660,304

G

microsomal glutathione S-transferase 3

increases expression

Pyrazinamide results in increased expression of MGST3 mRNA

NCBI chr13:79,526,541...79,547,479
Ensembl chr13:79,526,541...79,547,411

G

Mix paired-like homeobox 1

decreases expression

Pyrazinamide results in decreased expression of MIXL1 mRNA

NCBI chr13:92,422,031...92,426,065
Ensembl chr13:92,422,031...92,426,065

G

mitochondrial ribosomal protein S14

decreases expression

Pyrazinamide results in decreased expression of MRPS14 mRNA

NCBI chr13:72,429,168...72,434,915
Ensembl chr13:72,408,558...72,434,915

G

nuclear receptor subfamily 0, group B, member 2

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR0B2 mRNA]

NCBI chr 5:145,779,294...145,782,609
Ensembl chr 5:145,779,294...145,782,609

G

nuclear receptor subfamily 1, group H, member 4

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of NR1H4; obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of NR1H4 mRNA]
Pyrazinamide results in decreased expression of NR1H4 mRNA; Pyrazinamide results in decreased expression of NR1H4 protein

PMID:27255380 PMID:35835356

NCBI chr 7:23,846,122...23,942,085
Ensembl chr 7:23,846,122...23,942,047

G

NAD(P) dependent steroid dehydrogenase-like

increases expression

Pyrazinamide results in increased expression of NSDHL mRNA

NCBI chr X:150,775,034...150,807,161
Ensembl chr X:150,775,080...150,807,142

G

neurotrophic receptor tyrosine kinase 1

decreases expression

Pyrazinamide results in decreased expression of NTRK1 mRNA

NCBI chr 2:173,236,961...173,253,806
Ensembl chr 2:173,236,963...173,253,770

G

p53 apoptosis effector related to PMP22

increases expression

Pyrazinamide results in increased expression of PERP mRNA

NCBI chr 1:13,542,067...13,554,514
Ensembl chr 1:13,542,067...13,554,511

G

phosphoglycerate dehydrogenase

increases expression

Pyrazinamide results in increased expression of PHGDH mRNA

NCBI chr 2:185,906,962...185,936,054
Ensembl chr 2:185,906,966...185,935,944

G

peroxisome proliferator activated receptor alpha

multiple interactions
decreases expression

[Pyrazinamide co-treated with Glucose] binds to PPARA protein; Pyrazinamide inhibits the reaction [Glucose inhibits the reaction [Palmitoyl Coenzyme A analog binds to PPARA protein]]
Fenofibrate inhibits the reaction [Pyrazinamide results in decreased expression of PPARA mRNA]
Pyrazinamide results in decreased expression of PPARA mRNA; Pyrazinamide results in decreased expression of PPARA protein

PMID:18812576 PMID:27071702

NCBI chr 7:116,832,405...116,900,878
Ensembl chr 7:116,832,756...116,895,346

G

protein phosphatase 2 scaffold subunit A alpha

increases expression

Pyrazinamide results in increased expression of PPP2R1A mRNA

NCBI chr 1:60,540,223...60,559,467
Ensembl chr 1:60,540,194...60,560,129

G

prominin 1

decreases expression

Pyrazinamide results in decreased expression of PROM1 mRNA

NCBI chr14:66,989,545...67,094,534
Ensembl chr14:66,990,160...67,094,527

G

solute carrier family 10 member 1

increases expression
multiple interactions

Pyrazinamide results in increased expression of SLC10A1 mRNA; Pyrazinamide results in increased expression of SLC10A1 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of SLC10A1

PMID:27255380 PMID:35835356

NCBI chr 6:100,613,045...100,626,670
Ensembl chr 6:100,613,045...100,626,670

G

solute carrier family 16, member 11

decreases expression

Pyrazinamide results in decreased expression of SLC16A11 mRNA

NCBI chr10:54,929,129...54,933,021
Ensembl chr10:54,927,725...54,942,915

G

solute carrier family 17 member 1

increases expression

Pyrazinamide results in increased expression of SLC17A1 mRNA

NCBI chr17:41,219,461...41,255,199
Ensembl chr17:41,222,049...41,253,304

G

solute carrier family 22 member 12

affects activity

Pyrazinamide affects the activity of SLC22A12 protein

NCBI chr 1:203,845,039...203,852,496
Ensembl chr 1:203,845,048...203,853,555

G

solute carrier family 22 member 13

decreases expression

Pyrazinamide results in decreased expression of SLC22A13 mRNA

NCBI chr 8:118,922,367...118,934,020
Ensembl chr 8:118,922,367...118,953,635

G

solute carrier family 25, member 39

increases expression

Pyrazinamide results in increased expression of SLC25A39 mRNA

NCBI chr10:87,362,494...87,367,358
Ensembl chr10:87,362,490...87,367,260

G

solute carrier family 25 member 4

decreases expression

Pyrazinamide results in decreased expression of SLC25A4 mRNA

NCBI chr16:46,072,935...46,076,730
Ensembl chr16:46,072,939...46,076,733

G

solute carrier family 25, member 42

decreases expression

Pyrazinamide results in decreased expression of SLC25A42 mRNA

NCBI chr16:19,213,914...19,251,990
Ensembl chr16:19,213,950...19,237,025

G

solute carrier family 29 member 1

decreases expression

Pyrazinamide results in decreased expression of SLC29A1 mRNA

NCBI chr 9:15,399,661...15,414,203
Ensembl chr 9:15,399,612...15,414,203

G

solute carrier family 51 member A

decreases expression

Pyrazinamide results in decreased expression of SLC51A mRNA; Pyrazinamide results in decreased expression of SLC51A protein

NCBI chr11:68,299,086...68,313,485
Ensembl chr11:68,299,086...68,313,485

G

SLC51 subunit beta

multiple interactions
decreases expression

obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLC51B mRNA]
Pyrazinamide results in decreased expression of SLC51B mRNA; Pyrazinamide results in decreased expression of SLC51B protein

NCBI chr 8:65,931,891...65,939,953
Ensembl chr 8:65,931,890...65,940,145

G

solute carrier family 6 member 9

decreases expression

Pyrazinamide results in decreased expression of SLC6A9 mRNA

NCBI chr 5:131,374,562...131,408,733
Ensembl chr 5:131,374,542...131,408,728

G

solute carrier family 7 member 10

decreases expression

Pyrazinamide results in decreased expression of SLC7A10 mRNA

NCBI chr 1:87,829,084...87,845,073
Ensembl chr 1:87,829,175...87,845,071

G

solute carrier family 7 member 11

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]

NCBI chr 2:134,382,002...134,517,622
Ensembl chr 2:133,963,107...134,517,536

G

solute carrier organic anion transporter family, member 1a4

increases expression

Pyrazinamide results in increased expression of SLCO1A4 mRNA; Pyrazinamide results in increased expression of SLCO1A4 protein

NCBI chr 4:174,710,004...174,764,810
Ensembl chr 4:174,710,004...175,254,573

G

solute carrier organic anion transporter family member 1B2

decreases expression
multiple interactions

Pyrazinamide results in decreased expression of SLCO1B2 mRNA; Pyrazinamide results in decreased expression of SLCO1B2 protein
obeticholic acid inhibits the reaction [Pyrazinamide results in decreased expression of SLCO1B2 mRNA]

NCBI chr 4:174,551,463...174,619,988
Ensembl chr 4:174,551,480...174,619,981

G

solute carrier organic anion transporter family, member 4a1

decreases expression

Pyrazinamide results in decreased expression of SLCO4A1 mRNA

NCBI chr 3:167,559,177...167,578,307
Ensembl chr 3:167,559,316...167,578,305

G

spermidine synthase

increases expression

Pyrazinamide results in increased expression of SRM mRNA

NCBI chr 5:159,025,875...159,029,076
Ensembl chr 5:159,025,873...159,029,405

G

sulfotransferase family 1C member 2A

decreases expression

Pyrazinamide results in decreased expression of SULT1C2A mRNA

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:6,874,249...6,904,734

G

sulfotransferase family 2A member 1

decreases expression

Pyrazinamide results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113
Ensembl chr 1:74,911,100...75,508,134

G

TOPBP1-interacting checkpoint and replication regulator

decreases expression

Pyrazinamide results in decreased expression of TICRR mRNA

NCBI chr 1:133,597,618...133,639,513
Ensembl chr 1:133,597,716...133,639,523

G

transmembrane protein 176A

increases expression

Pyrazinamide results in increased expression of TMEM176A mRNA

NCBI chr 4:77,774,940...77,778,620
Ensembl chr 4:77,774,843...77,778,620

G

UDP glucuronosyltransferase 1 family, polypeptide A2

increases expression

Pyrazinamide results in increased expression of UGT1A2 mRNA

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:88,713,184...88,808,465

G

voltage-dependent anion channel 1

increases expression

Pyrazinamide results in increased expression of VDAC1 mRNA

NCBI chr10:36,532,306...36,559,642
Ensembl chr10:36,532,244...36,559,640

G

X-box binding protein 1

increases expression

Pyrazinamide results in increased expression of XBP1 mRNA alternative form

NCBI chr14:80,390,629...80,395,713
Ensembl chr14:80,390,643...80,395,693

G

tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein, eta

increases expression

Pyrazinamide results in increased expression of YWHAH mRNA

NCBI chr14:77,696,332...77,705,715
Ensembl chr14:77,696,333...77,705,741

rifabutin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions
decreases acetylation

AADAC mRNA affects the reaction [Rifabutin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifabutin]

NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734

G

ATP binding cassette subfamily B member 11

decreases activity

Rifabutin results in decreased activity of ABCB11 protein

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

increases expression

Rifabutin results in increased expression of ABCB1 mRNA

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

cytochrome P450, family 3, subfamily a, polypeptide 2

increases expression
affects activity
multiple interactions

Rifabutin results in increased expression of CYP3A4 mRNA
Rifabutin affects the activity of CYP3A4 protein
AADAC mRNA affects the reaction [Rifabutin results in increased expression of CYP3A4 mRNA]

PMID:16837568 PMID:21856291 PMID:37285043

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

nuclear receptor subfamily 1, group I, member 2

increases activity

Rifabutin results in increased activity of NR1I2 protein

NCBI chr11:62,460,213...62,496,665
Ensembl chr11:62,460,213...62,496,658

rifampicin

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

arylacetamide deacetylase

multiple interactions
increases hydrolysis
decreases acetylation

AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; bis(4-nitrophenyl)phosphate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Isoflurophate inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Phenylmethylsulfonyl Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Physostigmine inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]; Sodium Fluoride inhibits the reaction [AADAC protein results in decreased acetylation of Rifampin]
AADAC protein results in increased hydrolysis of Rifampin

PMID:21856291 PMID:22207054

NCBI chr 2:144,163,436...144,186,086
Ensembl chr 2:144,135,319...144,174,734

G

ATP binding cassette subfamily A member 1

decreases expression
increases expression

Rifampin results in decreased expression of ABCA1 mRNA; Rifampin results in decreased expression of ABCA1 protein
Rifampin results in increased expression of ABCA1 mRNA; Rifampin results in increased expression of ABCA1 protein

PMID:15883047 PMID:17088262

NCBI chr 5:67,678,267...67,801,162
Ensembl chr 5:67,681,297...67,801,170

G

ATP binding cassette subfamily A member 2

increases expression

Rifampin results in increased expression of ABCA2 mRNA

NCBI chr 3:8,244,515...8,264,545
Ensembl chr 3:8,244,639...8,264,537

G

ATP binding cassette subfamily A member 8

decreases expression

Rifampin results in decreased expression of ABCA8 mRNA

NCBI chr10:94,917,520...94,991,199
Ensembl chr10:94,917,520...94,990,988

G

ATP binding cassette subfamily B member 11

decreases expression
multiple interactions
decreases activity

Rifampin results in decreased expression of ABCB11 mRNA
[Rifampin co-treated with Isoniazid] results in decreased expression of ABCB11 protein
Rifampin results in decreased expression of ABCB11 protein
tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of ABCB11 protein]
Rifampin results in decreased activity of ABCB11 protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCB11 protein; Rifampin inhibits the reaction [ABCB11 protein results in increased transport of Taurocholic Acid]
Rifampin results in decreased expression of ABCB11 mRNA; Rifampin results in decreased expression of ABCB11 protein

PMID:12135489 PMID:16837569 PMID:20829430 PMID:24014644 PMID:25886055 More...

NCBI chr 3:54,016,854...54,112,797
Ensembl chr 3:54,017,127...54,112,730

G

ATP binding cassette subfamily B member 1A

multiple interactions
increases expression
decreases activity
affects activity

[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA; [NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein; [Rifampin binds to and results in increased activity of NR1I2 protein] promotes the reaction [ABCB1 protein results in decreased uptake of Doxorubicin]; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCB1 protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 mRNA]; mulberroside A inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in increased expression of ABCB1 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of ABCB1 protein]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of ABCB1 mRNA]; Resveratrol inhibits the reaction [Rifampin results in increased expression of ABCB1 protein]; Rifampin promotes the reaction [ABCB1 protein results in increased transport of Digoxin]; Rifampin promotes the reaction [NR1I2 protein binds to ABCB1 promoter]
Rifampin results in increased expression of ABCB1 mRNA; Rifampin results in increased expression of ABCB1 protein
[Rifampin metabolite results in decreased activity of ABCB1A protein] which results in decreased abundance of Adenosine Triphosphate
Rifampin affects the activity of ABCB1 protein

PMID:8632764 PMID:11744607 PMID:14722322 PMID:15276086 PMID:15290871 More...

NCBI chr 4:25,357,467...25,529,941
Ensembl chr 4:25,158,362...25,442,709

G

ATP binding cassette subfamily B member 4

increases expression

Rifampin results in increased expression of ABCB4 mRNA

NCBI chr 4:25,150,998...25,209,489
Ensembl chr 4:25,151,953...25,209,202

G

ATP binding cassette subfamily B member 6

increases expression

Rifampin results in increased expression of ABCB6 mRNA

NCBI chr 9:76,668,554...76,677,263
Ensembl chr 9:76,668,554...76,676,924

G

ATP binding cassette subfamily C member 1

increases expression

Rifampin results in increased expression of ABCC1 mRNA

PMID:17191263 PMID:35972551

NCBI chr10:528,961...655,179
Ensembl chr10:531,812...655,114

G

ATP binding cassette subfamily C member 10

increases expression

Rifampin results in increased expression of ABCC10 mRNA

NCBI chr 9:14,657,242...14,677,178
Ensembl chr 9:14,657,264...14,677,178

G

ATP binding cassette subfamily C member 2

affects export
multiple interactions
increases expression

ABCC2 protein affects the export of Rifampin
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] affects the expression of ABCC2 protein
Rifampin results in increased expression of ABCC2; Rifampin results in increased expression of ABCC2 mRNA; Rifampin results in increased expression of ABCC2 protein
[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein

PMID:11836020 PMID:12206135 PMID:15652233 PMID:16837569 PMID:16952291 More...

NCBI chr 1:242,664,657...242,723,239
Ensembl chr 1:242,664,657...242,723,238

G

ATP binding cassette subfamily C member 3

multiple interactions
increases expression
increases activity

[Rifampin co-treated with ABCC2 gene mutant form] results in increased expression of ABCC3 protein; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of ABCC3 mRNA; Rifampin inhibits the reaction [Decitabine results in increased expression of ABCC3 mRNA]
Rifampin results in increased expression of ABCC3 mRNA
Rifampin results in increased activity of ABCC3 protein

PMID:14570758 PMID:16837569 PMID:16952291 PMID:19041851 PMID:20832446 More...

NCBI chr10:79,296,681...79,342,749
Ensembl chr10:79,296,693...79,342,595

G

ATP binding cassette subfamily C member 5

increases expression

Rifampin results in increased expression of ABCC5 mRNA

NCBI chr11:80,473,809...80,567,257
Ensembl chr11:80,473,872...80,567,253

G

ATP binding cassette subfamily C member 6

increases expression

Rifampin results in increased expression of ABCC6 mRNA

NCBI chr 1:96,447,224...96,501,464
Ensembl chr 1:96,447,251...96,501,464

G

ATP binding cassette subfamily F member 1

increases expression

Rifampin results in increased expression of ABCF1 mRNA

NCBI chr20:2,802,519...2,815,433
Ensembl chr20:2,802,488...2,815,433

G

ATP binding cassette subfamily G member 1

increases expression

Rifampin results in increased expression of ABCG1 mRNA; Rifampin results in increased expression of ABCG1 protein

PMID:12040753 PMID:17088262

NCBI chr20:9,126,687...9,182,948
Ensembl chr20:9,126,687...9,182,948

G

ATP binding cassette subfamily G member 2

increases expression
multiple interactions

Rifampin results in increased expression of ABCG2 mRNA; Rifampin results in increased expression of ABCG2 protein
Rifampin promotes the reaction [Dextran Sulfate results in decreased expression of ABCG2 mRNA]; Rifampin promotes the reaction [Lipopolysaccharides results in decreased expression of ABCG2 mRNA]

PMID:16837569 PMID:27199754 PMID:35972551 PMID:38423481

NCBI chr 4:87,676,241...87,802,757
Ensembl chr 4:87,745,319...87,802,409

G

ATP binding cassette subfamily G member 8

increases expression

Rifampin results in increased expression of ABCG8 mRNA

NCBI chr 6:9,945,629...9,964,912
Ensembl chr 6:9,945,629...9,964,912

G

ABI family, member 3

decreases expression

Rifampin results in decreased expression of ABI3 mRNA

NCBI chr10:80,769,819...80,780,816
Ensembl chr10:80,769,822...80,780,816

G

acetyl-CoA carboxylase alpha

increases expression

Rifampin results in increased expression of ACACA mRNA

NCBI chr10:69,014,261...69,276,453
Ensembl chr10:69,014,170...69,276,457

G

angiotensin converting enzyme 2

decreases expression

Rifampin results in decreased expression of ACE2 mRNA

NCBI chr X:30,293,597...30,340,961
Ensembl chr X:30,293,589...30,340,977

G

acyl-CoA synthetase long-chain family member 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of ACSL4 protein

NCBI chr X:105,942,794...106,006,573
Ensembl chr X:105,942,799...106,006,427

G

actin related protein 10

increases expression

Rifampin results in increased expression of ACTR10 mRNA

NCBI chr 6:89,446,141...89,472,350
Ensembl chr 6:89,446,093...89,473,047

G

alcohol dehydrogenase 1C (class I), gamma polypeptide

increases expression

Rifampin results in increased expression of ADH1C mRNA

NCBI chr 2:226,797,303...226,808,892
Ensembl chr 2:226,797,303...226,808,892

G

adiponectin, C1Q and collagen domain containing

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of ADIPOQ mRNA

NCBI chr11:77,721,912...77,735,644
Ensembl chr11:77,721,912...77,735,564

G

adenosine A2a receptor

decreases expression

Rifampin results in decreased expression of ADORA2A mRNA

NCBI chr20:13,315,848...13,333,386
Ensembl chr20:13,315,853...13,333,386

G

ArfGAP with GTPase domain, ankyrin repeat and PH domain 2

decreases expression

Rifampin results in decreased expression of AGAP2 mRNA

NCBI chr 7:62,897,282...62,914,295
Ensembl chr 7:62,897,282...62,914,295

G

aryl hydrocarbon receptor

multiple interactions
increases expression

[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in decreased expression of AHR mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of AHR protein; NR1I2 protein inhibits the reaction [[Rifampin co-treated with Benzo(a)pyrene] results in increased expression of AHR mRNA]
Rifampin results in increased expression of AHR mRNA; Rifampin results in increased expression of AHR protein

PMID:22733800 PMID:28428138

NCBI chr 6:52,234,089...52,271,568
Ensembl chr 6:52,234,089...52,271,568

G

aldo-keto reductase family 1 member B10

increases expression
multiple interactions

Rifampin results in increased expression of AKR1B10 mRNA
pazopanib inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of AKR1B10 mRNA]

NCBI chr 4:63,038,459...63,060,336
Ensembl chr 4:63,040,169...63,053,852

G

5'-aminolevulinate synthase 1

increases expression

Rifampin results in increased expression of ALAS1 mRNA

PMID:24259679 PMID:24552687

NCBI chr 8:106,876,514...106,889,917
Ensembl chr 8:106,876,514...106,889,917

G

alkaline phosphatase, biomineralization associated

increases activity
multiple interactions

Rifampin results in increased activity of ALPL protein
[Rifampin co-treated with Isoniazid] results in increased activity of ALPL protein

NCBI chr 5:149,951,397...150,006,424
Ensembl chr 5:149,951,409...150,006,446

G

angiopoietin-like 3

decreases expression

Rifampin results in decreased expression of ANGPTL3 mRNA

NCBI chr 5:113,703,007...113,710,044
Ensembl chr 5:113,703,012...113,709,957

G

angiopoietin-like 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of ANGPTL4 mRNA

NCBI chr 7:14,550,288...14,557,797
Ensembl chr 7:14,550,311...14,556,519

G

ankyrin repeat domain 40

increases expression

Rifampin results in increased expression of TMPRSS2 mRNA

NCBI chr10:79,282,075...79,295,322
Ensembl chr10:79,282,075...79,295,320
Ensembl chr10:79,282,075...79,295,320

G

ankyrin repeat domain 65

decreases expression

Rifampin results in decreased expression of ANKRD65 mRNA

NCBI chr 5:166,398,359...166,400,616
Ensembl chr 5:166,397,748...166,400,953

G

ankyrin repeat and sterile alpha motif domain containing 1B

decreases expression

Rifampin results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:24,312,843...25,477,693

G

annexin A5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of ANXA5 mRNA

NCBI chr 2:119,314,007...119,344,703
Ensembl chr 2:119,314,007...119,353,369

G

apolipoprotein B

decreases expression
multiple interactions
affects secretion

Rifampin results in decreased expression of APOB mRNA
ursodoxicoltaurine inhibits the reaction [Rifampin results in decreased expression of APOB mRNA]
Rifampin affects the secretion of APOB protein

NCBI chr 6:30,844,386...30,883,983
Ensembl chr 6:30,844,368...30,892,497

G

apolipoprotein C3

decreases expression
decreases secretion

Rifampin results in decreased expression of APOC3 mRNA
Rifampin results in decreased secretion of APOC3 protein

NCBI chr 8:46,531,478...46,533,658
Ensembl chr 8:46,531,478...46,533,583

G

aquaporin 3 (Gill blood group)

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of AQP3 mRNA

NCBI chr 5:56,239,200...56,244,718
Ensembl chr 5:56,239,201...56,244,720

G

aquaporin 4

decreases expression

Rifampin results in decreased expression of AQP4 mRNA

NCBI chr18:6,507,903...6,524,558
Ensembl chr18:6,507,903...6,524,856

G

arylsulfatase family, member J

decreases expression

Rifampin results in decreased expression of ARSJ mRNA

NCBI chr 2:214,774,631...214,854,614
Ensembl chr 2:214,774,654...214,854,612

G

activating transcription factor 3

multiple interactions

[Rifampin co-treated with Cobicistat] results in increased expression of ATF3 mRNA

NCBI chr13:102,751,278...102,800,520
Ensembl chr13:102,751,321...102,764,631

G

activating transcription factor 4

multiple interactions
increases expression

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
Rifampin results in increased expression of ATF4 mRNA; Rifampin results in increased expression of ATF4 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of ATF4 protein]

PMID:24638036 PMID:27470132

NCBI chr 7:111,804,135...111,806,457
Ensembl chr 7:111,804,183...111,806,446

G

activating transcription factor 6

increases expression

Rifampin results in increased expression of ATF6 mRNA

NCBI chr13:82,927,579...83,106,381
Ensembl chr13:82,930,034...83,107,177

G

ATM serine/threonine kinase

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of ATM protein
Rifampin results in decreased expression of ATM mRNA

PMID:21224054 PMID:24552687

NCBI chr 8:53,828,741...53,932,773
Ensembl chr 8:53,831,093...53,932,437

G

ATPase H+ transporting V0 subunit a1

increases expression
multiple interactions

Rifampin results in increased expression of ATP6V0A1 protein
[Rotenone co-treated with Rifampin] results in increased expression of ATP6V0A1 protein; Rifampin inhibits the reaction [Rotenone results in decreased expression of ATP6V0A1 mRNA]; Rotenone inhibits the reaction [Rifampin results in increased expression of ATP6V0A1 protein]

NCBI chr10:85,935,802...85,989,901
Ensembl chr10:85,935,854...85,989,895

G

ATPase H+ transporting V0 subunit D1

multiple interactions

ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]

NCBI chr19:33,403,352...33,447,357
Ensembl chr19:33,403,355...33,447,450

G

ATRX, chromatin remodeler

increases expression

Rifampin results in increased expression of ATRX mRNA

NCBI chr X:70,850,981...70,997,330
Ensembl chr X:70,850,981...70,997,330

G

BCL2 associated X, apoptosis regulator

multiple interactions
decreases expression

[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BAX mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of BAX mRNA; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of BAX protein]
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein
Rifampin results in decreased expression of BAX protein

PMID:11958592 PMID:12645856 PMID:21224054 PMID:21419764 PMID:31629065 More...

NCBI chr 1:95,940,001...95,945,407
Ensembl chr 1:95,938,808...95,945,368

G

BCL2, apoptosis regulator

increases expression
multiple interactions

Rifampin results in increased expression of BCL2 protein
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein
[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of BCL2 protein]

PMID:11958592 PMID:21419764 PMID:31629065

NCBI chr13:22,689,783...22,853,920
Ensembl chr13:22,684,989...22,853,743
Ensembl chr13:22,684,989...22,853,743

G

Bcl2-like 1

increases expression
multiple interactions

Rifampin results in increased expression of BCL2L1 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of BCL2L1 mRNA

PMID:11958592 PMID:12645856 PMID:21224054

NCBI chr 3:141,253,508...141,304,582
Ensembl chr 3:141,253,523...141,303,479
Ensembl chr 1:141,253,523...141,303,479

G

basic helix-loop-helix family, member e40

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of BHLHE40 mRNA

NCBI chr 4:141,618,453...141,624,154
Ensembl chr 4:141,618,476...141,624,774

G

bone morphogenetic protein 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of BMP4 mRNA

NCBI chr15:19,618,538...19,633,494
Ensembl chr15:19,618,542...19,623,306

G

similar to human chromosome 9 open reading frame 153

decreases expression

Rifampin results in decreased expression of C9ORF153 mRNA

NCBI chr17:4,975,415...4,982,400
Ensembl chr17:4,964,834...4,982,766

G

similar to human chromosome 4 open reading frame 51

decreases expression

Rifampin results in decreased expression of C4ORF51 mRNA

NCBI chr19:28,669,044...28,704,512
Ensembl chr19:28,669,059...28,704,508

G

carbonic anhydrase 1

decreases expression

Rifampin results in decreased expression of CA1 mRNA

NCBI chr 2:86,829,436...86,872,209
Ensembl chr 2:86,861,897...86,872,208

G

caspase 1

multiple interactions

Rifampin inhibits the reaction [Rotenone results in increased cleavage of CASP1 protein]

NCBI chr 8:2,587,812...2,597,403
Ensembl chr 8:2,587,831...2,597,383

G

caspase 3

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Rifampin inhibits the reaction [[Acetaminophen co-treated with [ferric nitrate results in increased abundance of Iron]] results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [Doxorubicin results in increased cleavage of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [Staurosporine results in increased cleavage of CASP3 protein]; Rifampin promotes the reaction [Galactosamine results in increased activity of CASP3 protein]
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CASP3
[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]; Ursodeoxycholic Acid inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

PMID:11958592 PMID:12645856 PMID:17936189 PMID:21419764 PMID:23764483 More...

NCBI chr16:45,662,910...45,681,171
Ensembl chr16:45,662,910...45,684,648

G

caspase 8

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]

PMID:11958592 PMID:12645856

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:60,264,075...60,312,542

G

catalase

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CAT protein

NCBI chr 3:89,842,393...89,874,577
Ensembl chr 3:89,842,399...89,874,478

G

carbonyl reductase 3

multiple interactions

[Rifampin co-treated with Cobicistat] results in increased expression of CBR3 mRNA

NCBI chr11:33,008,615...33,016,877
Ensembl chr11:33,008,615...33,016,875

G

C-C motif chemokine ligand 2

decreases expression

Rifampin results in decreased expression of CCL2 mRNA

NCBI chr10:67,005,424...67,007,222
Ensembl chr10:67,005,424...67,007,226

G

C-C motif chemokine ligand 5

decreases expression

Rifampin results in decreased expression of CCL5 protein

NCBI chr10:68,322,826...68,327,380
Ensembl chr10:68,322,829...68,327,377

G

cellular communication network factor 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCN1 mRNA

NCBI chr 2:234,562,410...234,565,370
Ensembl chr 2:234,562,408...234,565,484

G

cyclin D1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CCND1 mRNA

NCBI chr 1:200,089,002...200,098,524
Ensembl chr 1:200,089,002...200,098,602

G

cyclin G1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CCNG1 mRNA

NCBI chr10:25,176,231...25,182,604
Ensembl chr10:25,176,234...25,181,641

G

C-C motif chemokine receptor 6

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR6 mRNA

NCBI chr 1:52,474,477...52,508,301
Ensembl chr 1:52,474,168...52,498,603

G

C-C motif chemokine receptor 7

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CCR7 mRNA

NCBI chr10:84,098,193...84,108,309
Ensembl chr10:84,097,381...84,108,309

G

CD36 molecule

increases expression

Rifampin results in increased expression of CD36 mRNA

NCBI chr 4:17,317,343...17,410,084
Ensembl chr 4:17,354,466...17,513,903

G

cyclin-dependent kinase inhibitor 1A

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A mRNA; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CDKN1A protein

NCBI chr20:7,149,177...7,159,727
Ensembl chr20:7,149,217...7,159,585

G

cyclin-dependent kinase inhibitor 2B

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CDKN2B mRNA

NCBI chr 5:104,009,839...104,019,082
Ensembl chr 5:104,010,680...104,019,050

G

CCAAT/enhancer binding protein alpha

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPA mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]

NCBI chr 1:87,759,631...87,762,303
Ensembl chr 1:87,759,433...87,762,412

G

CCAAT/enhancer binding protein beta

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPB mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]

NCBI chr 3:156,398,035...156,399,466
Ensembl chr 3:156,397,052...156,399,473

G

CCAAT/enhancer binding protein delta

multiple interactions

[Rifampin affects the susceptibility to Dietary Fats] which results in decreased expression of CEBPD mRNA; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]

NCBI chr11:84,764,670...84,765,808
Ensembl chr11:84,764,565...84,765,829

G

carboxylesterase 1D

increases expression

Rifampin results in increased expression of CES1 protein

NCBI chr19:13,873,490...13,912,035
Ensembl chr19:13,796,623...13,912,035

G

carboxylesterase 2H

increases expression
multiple interactions

Rifampin results in increased expression of CES2 mRNA; Rifampin results in increased expression of CES2 protein
Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CES2 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CES2 mRNA]

PMID:10640517 PMID:17003103

NCBI chr19:32,974,242...32,988,842
Ensembl chr19:32,974,242...32,988,830

G

CASP8 and FADD-like apoptosis regulator

multiple interactions
increases expression

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]
Rifampin results in increased expression of CFLAR protein

PMID:11958592 PMID:12645856

NCBI chr 9:60,185,338...60,236,173
Ensembl chr 9:60,185,452...60,237,034

G

checkpoint kinase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CHEK2 mRNA

NCBI chr12:45,788,823...45,821,382
Ensembl chr12:45,788,827...45,821,286

G

CDKN1A interacting zinc finger protein 1

decreases expression

Rifampin results in decreased expression of CIZ1 mRNA

NCBI chr 3:15,658,479...15,673,762
Ensembl chr 3:15,658,539...15,673,762

G

CDC-like kinase 2

decreases expression

Rifampin results in decreased expression of CLK2 mRNA

NCBI chr 2:174,570,614...174,582,645
Ensembl chr 2:174,570,653...174,588,985

G

centlein

increases expression

Rifampin results in increased expression of CNTLN mRNA

NCBI chr 5:99,295,865...99,576,402
Ensembl chr 5:99,296,000...99,576,396

G

carnitine palmitoyltransferase 1A

increases expression

Rifampin results in increased expression of CPT1A mRNA

NCBI chr 1:200,564,634...200,627,059
Ensembl chr 1:200,565,613...200,627,055

G

corticotropin releasing hormone receptor 1

decreases expression

Rifampin results in decreased expression of CRHR1 mRNA

NCBI chr10:89,040,186...89,083,481
Ensembl chr10:89,040,203...89,083,481

G

C-reactive protein

multiple interactions

[Floxacillin co-treated with Gentamicins co-treated with Rifampin] results in increased expression of CRP protein

NCBI chr13:85,135,384...85,175,178
Ensembl chr13:85,124,977...85,175,178

G

casein kinase 1, gamma 1

decreases expression

Rifampin results in decreased expression of CSNK1G1 mRNA

NCBI chr 8:66,439,760...66,577,247
Ensembl chr 8:66,439,864...66,572,826

G

C-X-C motif chemokine ligand 1

increases expression

Rifampin results in increased expression of CXCL1 protein

NCBI chr14:17,193,364...17,195,143
Ensembl chr14:17,193,365...17,195,215

G

C-X-C motif chemokine ligand 10

multiple interactions
affects expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CXCL10 mRNA
Rifampin affects the expression of CXCL10 protein

PMID:21224054 PMID:25051504

NCBI chr14:15,704,772...15,706,969
Ensembl chr14:15,704,758...15,706,975

G

cytochrome b5 reductase-like

increases expression

Rifampin results in increased expression of CYB5RL mRNA

NCBI chr 5:121,846,223...121,868,287
Ensembl chr 5:121,847,952...121,868,745

G

cytochrome P450, family 1, subfamily a, polypeptide 1

multiple interactions
increases activity
increases expression

Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]
Rifampin results in increased activity of CYP1A1 protein
Rifampin results in increased expression of CYP1A1 mRNA; Rifampin results in increased expression of CYP1A1 protein
[Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP1A1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP1A1 protein; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A1 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein]

PMID:12040753 PMID:18493746 PMID:19118567 PMID:19409404 PMID:22733800 More...

NCBI chr 8:58,096,021...58,102,130
Ensembl chr 8:58,096,077...58,102,125

G

cytochrome P450, family 1, subfamily a, polypeptide 2

multiple interactions
increases expression

[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1A2 mRNA; Rifampin inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP1A2 protein; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 mRNA]; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in decreased expression of CYP1A2 protein]
Rifampin results in increased expression of CYP1A2 mRNA; Rifampin results in increased expression of CYP1A2 protein

PMID:15977188 PMID:17590308 PMID:18493746 PMID:25835148 PMID:29162470 More...

NCBI chr 8:58,075,367...58,082,255
Ensembl chr 8:58,075,367...58,082,312

G

cytochrome P450, family 1, subfamily b, polypeptide 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP1B1 mRNA
[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP1B1 mRNA

PMID:21224054 PMID:29162470

NCBI chr 6:15,342,312...15,350,886
Ensembl chr 6:15,342,344...15,350,917

G

cytochrome P450, family 24, subfamily a, polypeptide 1

multiple interactions
increases expression
increases activity

NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP24A1 mRNA]; Rifampin promotes the reaction [NR1I2 protein binds to CYP24A1 promoter]
Rifampin results in increased activity of CYP24A1 protein

PMID:15630458 PMID:21127053

NCBI chr 3:159,275,947...159,290,383
Ensembl chr 3:159,275,947...159,290,383

G

cytochrome P450, family 26, subfamily a, polypeptide 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP26A1 mRNA

NCBI chr 1:235,471,368...235,475,204
Ensembl chr 1:235,471,298...235,475,204

G

cytochrome P450, family 27, subfamily a, polypeptide 1

multiple interactions
increases expression

Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]
Rifampin results in increased expression of CYP27A1 mRNA

NCBI chr 9:76,264,655...76,294,551
Ensembl chr 9:76,264,860...76,294,551

G

cytochrome P450, family 2, subfamily a, polypeptide 1

increases expression
decreases expression

Rifampin results in increased expression of CYP2A1 mRNA
Rifampin results in increased expression of CYP2A13 mRNA
Rifampin results in decreased expression of CYP2A13 mRNA

PMID:19118567 PMID:22258563

NCBI chr 1:82,231,611...82,244,887
Ensembl chr 1:82,231,611...82,244,887

G

cytochrome P450, family 2, subfamily a, polypeptide 3

increases expression

Rifampin results in increased expression of CYP2A4 mRNA

NCBI chr 1:82,171,914...82,179,980
Ensembl chr 1:82,169,949...82,179,979

G

cytochrome P450, family 2, subfamily b, polypeptide 3

increases activity
multiple interactions
increases expression

Rifampin results in increased activity of CYP2B6 protein
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2B10 protein; [Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B10 mRNA
Rifampin results in increased expression of CYP2B6 mRNA; Rifampin results in increased expression of CYP2B6 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2B6 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2B6 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2B6 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP2B6 mRNA; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Dexamethasone promotes the reaction [NR3C1 protein affects the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]]]; Dexamethasone promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of and results in increased activity of CYP2B6 protein]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP2B6 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP2B6 protein

PMID:12040753 PMID:12571232 PMID:12695351 PMID:14709624 PMID:14977870 More...

NCBI chr 1:81,652,762...81,732,153
Ensembl chr 1:81,652,787...81,732,143

G

cytochrome P450, subfamily 2, polypeptide 11

decreases expression

Rifampin results in decreased expression of CYP2C18 mRNA; Rifampin results in decreased expression of CYP2C18 protein

PMID:22258563 PMID:31629065

NCBI chr 1:236,762,719...236,799,069
Ensembl chr 1:236,762,842...236,799,066

G

cytochrome P450, family 2, subfamily C, polypeptide 6

increases activity
increases expression
multiple interactions

Rifampin results in increased activity of CYP2C19 protein
Rifampin results in increased expression of CYP2C29 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in increased expression of CYP2C protein
Rifampin results in increased expression of CYP2C19 mRNA; Rifampin results in increased expression of CYP2C19 protein
Rifampin results in increased expression of and results in increased activity of CYP2C19 protein

PMID:12584154 PMID:14709624 PMID:15629111 PMID:17954527 PMID:19118567 More...

NCBI chr 1:237,938,521...237,976,238
Ensembl chr 1:237,693,094...238,057,596

G

cytochrome P450, family 2, subfamily c, polypeptide 79

affects binding
multiple interactions
increases expression
increases activity

[Rifampin binds to NR1I2 protein] which binds to CYP2C8 promoter
[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of BCL2 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein; [Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in increased expression of BAX protein; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; pimecrolimus inhibits the reaction [Rifampin results in increased expression of CYP2C8 mRNA]; Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]
Rifampin results in increased expression of CYP2C8 mRNA; Rifampin results in increased expression of CYP2C8 protein
Rifampin results in increased activity of CYP2C8 protein

PMID:12040753 PMID:15771232 PMID:15933212 PMID:17954527 PMID:19118567 More...

G

cytochrome P450, family 2, subfamily d, polypeptide 4

increases expression
increases activity
decreases expression

Rifampin results in increased expression of CYP2D6 mRNA
Rifampin results in increased activity of CYP2D6 protein
Rifampin results in decreased expression of CYP2D22 mRNA

PMID:19041851 PMID:30503582 PMID:33844597

NCBI chr 7:113,882,584...113,891,754
Ensembl chr 7:113,881,618...113,891,759

G

cytochrome P450, family 2, subfamily e, polypeptide 1

increases activity
decreases expression
multiple interactions
increases expression

Rifampin results in increased activity of CYP2E1 protein
Rifampin results in decreased expression of CYP2E1 mRNA
[[NR1I3 protein co-treated with NR1I2 protein] results in increased susceptibility to Rifampin] which results in decreased expression of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with dendrobine] results in decreased expression of CYP2E1 mRNA; [Isoniazid co-treated with Rifampin] results in decreased expression of CYP2E1 mRNA
Rifampin results in increased expression of CYP2E1 mRNA; Rifampin results in increased expression of CYP2E1 protein
[Rifampin co-treated with Monocrotophos] results in increased activity of CYP2E1 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP2E1 protein
[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein; [Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased activity of CYP2E1 protein]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP2E1 mRNA]; Rifampin inhibits the reaction [Isoniazid results in increased expression of CYP2E1 protein]

PMID:15132840 PMID:18071298 PMID:22258563 PMID:22733800 PMID:25835148 More...

NCBI chr 1:195,840,330...195,850,728
Ensembl chr 1:195,840,058...195,864,023

G

cytochrome P450, family 2, subfamily f, polypeptide 4

decreases expression

Rifampin results in decreased expression of CYP2F1 mRNA

NCBI chr 1:82,416,107...82,429,897
Ensembl chr 1:82,416,130...82,429,896

G

cytochrome P450, family 2, subfamily j, polypeptide 4

decreases expression

Rifampin results in decreased expression of CYP2J2 mRNA

NCBI chr 5:111,179,981...111,207,490
Ensembl chr 5:111,178,703...111,244,794

G

cytochrome P450, family 2, subfamily s, polypeptide 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP2S1 mRNA

NCBI chr 1:81,309,948...81,325,303
Ensembl chr 1:81,310,451...81,325,303

G

cytochrome P450, family 3, subfamily a, polypeptide 2

multiple interactions
affects activity
increases expression
decreases response to substance
increases activity

[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA; [Methionine co-treated with Thiamine co-treated with Niacinamide co-treated with alpha-Tocopherol co-treated with Zinc] inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A2 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A2 mRNA]; Methionine inhibits the reaction [[Isoniazid co-treated with Rifampin co-treated with Ethambutol co-treated with Pyrazinamide] results in increased expression of CYP3A2 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A2 protein
Rifampin affects the activity of CYP3A4 protein
Rifampin results in increased expression of CYP3A4; Rifampin results in increased expression of CYP3A4 mRNA; Rifampin results in increased expression of CYP3A4 mRNA alternative form; Rifampin results in increased expression of CYP3A4 protein
[[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein] which results in increased metabolism of and results in increased activity of and results in increased susceptibility to Cobicistat; [Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA; [HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Methylcholanthrene co-treated with Rifampin co-treated with Phenobarbital] results in increased expression of CYP3A4 mRNA; [NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; [NR1I2 protein co-treated with Rifampin] results in decreased expression of CYP3A4 mRNA; [PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin binds to CYP3A4 promoter] which results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased activity of CYP3A4 protein; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of CYP3A4 protein; [Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A4 mRNA; [Rifampin results in increased activity of NR1I2 protein] which results in increased expression of CYP3A4 mRNA; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Ethinyl Estradiol; [Rifampin results in increased expression of CYP3A4 protein] which results in decreased abundance of Midazolam; [Rifampin results in increased expression of CYP3A4 protein] which results in increased hydroxylation of Testosterone; [Rifampin results in increased expression of NR1I2 protein] which results in increased expression of and results in increased activity of CYP3A4 protein; [RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; AADAC mRNA affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Arsenic Trioxide inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Calcitriol promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Camptothecin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 1-hydroxymethylmidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased chemical synthesis of 4-hydroxymidazolam]; CYP3A4 protein inhibits the reaction [Rifampin results in decreased hydroxylation of Midazolam]; Dexamethasone promotes the reaction [Rifampin results in increased activity of CYP3A4 protein]; Dichlororibofuranosylbenzimidazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Econazole promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Galactosamine inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; GW 3965 inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; Ketoconazole inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Ketoconazole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; lorlatinib inhibits the reaction [Rifampin results in increased activity of CYP3A4 protein]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Metformin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]]; NR1H3 mutant form inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 gene promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 mRNA promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein affects the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR1I2 protein inhibits the reaction [Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[PPARGC1A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[RXRA protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [[SRC protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; NR1I2 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 protein]; NR3C1 protein promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; ochratoxin A inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; oxiconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]]; periodate-oxidized adenosine inhibits the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [[Dimethyl Sulfoxide results in increased susceptibility to Rifampin] which results in increased expression of CYP3A4 mRNA]; PRMT1 protein affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; PRMT1 protein affects the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin binds to and results in increased activity of CYP3A4 protein; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased chemical synthesis of 4-hydroxymidazolam]; Rifampin inhibits the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[RXRA protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [Calcitriol results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [CYP3A4 protein results in increased chemical synthesis of 1-hydroxymethylmidazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased hydroxylation of Midazolam]; Rifampin promotes the reaction [CYP3A4 protein results in increased metabolism of Lidocaine]; Rifampin promotes the reaction [NR1I2 protein binds to CYP3A4 promoter]; Rifampin promotes the reaction [NR1I2 protein results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NR1I2 results in increased expression of CYP3A4 mRNA]; Rifampin results in increased expression of and results in increased activity of CYP3A4 protein; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Skatole inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A4 protein]; sodium arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; sulforaphane inhibits the reaction [Rifampin results in increased expression of CYP3A4]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Tetrachlorodibenzodioxin inhibits the reaction [Rifampin results in increased expression of CYP3A4 protein]; Thapsigargin inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; trichostatin A affects the reaction [Dimethyl Sulfoxide promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]]; trichostatin A promotes the reaction [Rifampin results in increased expression of CYP3A4 mRNA]
CYP3A4 protein results in decreased susceptibility to Rifampin
[Rifampin results in increased activity of NR1I2 protein] which results in increased activity of CYP3A4 protein; Rifampin results in increased activity of CYP3A4 protein
Rifampin results in increased expression of CYP3A2 mRNA; Rifampin results in increased expression of CYP3A4 mRNA

PMID:8632764 PMID:9298257 PMID:9512926 PMID:10219967 PMID:10640517 More...

NCBI chr12:9,207,978...9,230,064
Ensembl chr12:9,015,383...9,285,008

G

cytochrome P450, family 3, subfamily a, polypeptide 23-polypeptide 1

multiple interactions
increases expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA; arsenite inhibits the reaction [Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein]; arsenite inhibits the reaction [Rifampin results in increased expression of CYP3A23-3A1 mRNA]; Rifampin promotes the reaction [[NR1I2 protein co-treated with RXRA protein] binds to CYP3A23-3A1 promoter]; Rifampin results in increased expression of and results in increased activity of CYP3A23-3A1 protein; sodium arsenite inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of CYP3A23-3A1 mRNA]

PMID:12370413 PMID:19041297 PMID:22159698 PMID:22310326

NCBI chr12:9,256,159...9,285,020
Ensembl chr12:9,254,475...9,285,030
Ensembl chr12:9,254,475...9,285,030

G

cytochrome P450, family 3, subfamily a, polypeptide 9

increases expression

Rifampin results in increased expression of CYP3A5 mRNA

PMID:12040753 PMID:12673034 PMID:15629111 PMID:15681896 PMID:19118567 More...

NCBI chr12:16,806,222...16,846,428
Ensembl chr12:16,806,207...16,846,422

G

cytochrome P450 family 7 subfamily A member 1

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of CYP7A1 protein
Rifampin results in decreased expression of CYP7A1 mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of CYP7A1 protein; NR1I2 protein promotes the reaction [Rifampin results in decreased expression of CYP7A1 mRNA]

PMID:15629111 PMID:21127053 PMID:21224054 PMID:22258563 PMID:24259679 More...

NCBI chr 5:19,376,979...19,386,676
Ensembl chr 5:19,376,974...19,386,688

G

cytochrome P450 family 8 subfamily B member 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of CYP8B1 mRNA

NCBI chr 8:121,578,123...121,580,093
Ensembl chr 8:121,557,062...121,580,166

G

DDB1 and CUL4 associated factor 5

decreases expression

Rifampin results in decreased expression of DCAF5 mRNA

NCBI chr 6:99,171,506...99,260,183
Ensembl chr 6:99,171,506...99,260,110

G

DNA cross-link repair 1B

decreases expression

Rifampin results in decreased expression of DCLRE1B mRNA

NCBI chr 2:191,309,909...191,318,399
Ensembl chr 2:191,309,913...191,318,423

G

DNA-damage inducible transcript 3

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of DDIT3 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of DDIT3 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of DDIT3 mRNA]
Rifampin results in increased expression of DDIT3 mRNA; Rifampin results in increased expression of DDIT3 protein

PMID:21224054 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr 7:63,115,645...63,121,203
Ensembl chr 7:63,116,380...63,121,201

G

24-dehydrocholesterol reductase

multiple interactions

[Rifampin results in increased activity of NR1I2 protein] which results in increased expression of DHCR24 mRNA

NCBI chr 5:121,344,552...121,371,124
Ensembl chr 5:121,344,575...121,371,137

G

iodothyronine deiodinase 1

increases expression

Rifampin results in increased expression of DIO1 mRNA

NCBI chr 5:122,074,285...122,090,983
Ensembl chr 5:122,074,279...122,090,970

G

distal-less homeobox 4

decreases expression

Rifampin results in decreased expression of DLX4 mRNA

NCBI chr10:80,085,037...80,090,434
Ensembl chr10:80,085,465...80,090,456

G

DnaJ heat shock protein family (Hsp40) member A1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of DNAJA1 mRNA

NCBI chr 5:55,842,414...55,853,326
Ensembl chr 5:55,842,426...55,853,967

G

E2F transcription factor 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of E2F1 mRNA

NCBI chr 3:143,064,535...143,075,362
Ensembl chr 3:143,049,478...143,075,361

G

endothelin 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EDN1 mRNA

NCBI chr17:22,454,924...22,460,812
Ensembl chr17:22,454,420...22,460,885

G

early growth response 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of EGR1 mRNA
[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR1 mRNA

PMID:21127053 PMID:21224054

NCBI chr18:26,462,967...26,466,766
Ensembl chr18:26,462,981...26,466,766

G

early growth response 2

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR2 mRNA

NCBI chr20:21,051,270...21,056,322
Ensembl chr20:21,051,277...21,055,562

G

early growth response 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EGR4 mRNA

NCBI chr 4:118,047,869...118,050,328
Ensembl chr 4:118,047,869...118,050,328

G

eukaryotic translation initiation factor 2 alpha kinase 3

increases phosphorylation
increases expression
multiple interactions

Rifampin results in increased phosphorylation of EIF2AK3 protein
Rifampin results in increased expression of EIF2AK3 mRNA; Rifampin results in increased expression of EIF2AK3 protein
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of EIF2AK3 protein]

PMID:24638036 PMID:27470132

NCBI chr 4:102,805,495...102,866,914
Ensembl chr 4:102,805,510...102,866,911

G

eukaryotic translation initiation factor 2 subunit alpha

increases phosphorylation

Rifampin results in increased phosphorylation of EIF2S1 protein

NCBI chr 6:97,672,829...97,697,499
Ensembl chr 6:97,672,766...97,706,225

G

ETS transcription factor ELK1

decreases expression

Rifampin results in decreased expression of ELK1 mRNA

NCBI chr X:1,138,826...1,155,713
Ensembl chr X:1,139,756...1,155,713

G

endothelial PAS domain protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of EPAS1 mRNA

NCBI chr 6:7,790,236...7,871,717
Ensembl chr 6:7,790,647...7,871,228

G

epoxide hydrolase 1

increases expression
multiple interactions

Rifampin results in increased expression of EPHX1 mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of EPHX1 mRNA]

PMID:22258563 PMID:25313206 PMID:29356861

NCBI chr13:92,714,315...92,744,105
Ensembl chr13:92,714,315...92,790,235

G

endoplasmic reticulum to nucleus signaling 1

multiple interactions
increases expression

Rifampin results in increased expression of and results in increased phosphorylation of ERN1 protein
Rifampin results in increased expression of ERN1 mRNA

NCBI chr10:91,326,889...91,421,201
Ensembl chr10:91,330,654...91,421,029

G

ethanolamine-phosphate phospho-lyase

increases expression

Rifampin results in increased expression of ETNPPL mRNA

NCBI chr 2:219,173,048...219,194,646
Ensembl chr 2:219,172,978...219,192,212

G

coagulation factor XIII B chain

increases expression

Rifampin results in increased expression of F13B mRNA

NCBI chr13:51,130,908...51,156,383
Ensembl chr13:51,130,920...51,156,381

G

Fas cell surface death receptor

multiple interactions

Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]]; Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP3 protein]; Rifampin inhibits the reaction [FAS protein results in increased activity of CASP8 protein]; Rifampin inhibits the reaction [FAS protein results in increased expression of CFLAR protein modified form]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856

NCBI chr 1:231,798,963...231,832,591
Ensembl chr 1:231,798,960...231,832,591

G

Fas ligand

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FASL mRNA
Rifampin results in decreased expression of FASLG mRNA; Rifampin results in decreased expression of FASLG protein
Mifepristone inhibits the reaction [Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]]; Rifampin inhibits the reaction [FAS protein results in increased expression of FASLG protein]

PMID:11958592 PMID:12645856 PMID:21224054 PMID:24552687

NCBI chr13:74,151,519...74,172,760
Ensembl chr13:74,154,954...74,162,215

G

fatty acid synthase

increases expression
affects expression
multiple interactions

Rifampin results in increased expression of FASN mRNA
Rifampin affects the expression of FASN mRNA
pimecrolimus inhibits the reaction [Rifampin results in increased expression of FASN mRNA]

PMID:27806127 PMID:29356861 PMID:34689256

NCBI chr10:106,072,093...106,090,259
Ensembl chr10:106,072,091...106,090,261

G

fibroblast growth factor 19

multiple interactions
increases expression

[Rifampin binds to and results in increased activity of NR1I2 protein] which results in increased expression of FGF19 mRNA
Rifampin results in increased expression of FGF19 mRNA

NCBI chr 1:200,056,526...200,060,980
Ensembl chr 1:200,056,644...200,060,287

G

flavin containing dimethylaniline monoxygenase 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO1 mRNA

NCBI chr13:75,182,184...75,214,439
Ensembl chr13:75,182,176...75,214,647

G

flavin containing dimethylaniline monoxygenase 4

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of FMO4 mRNA

NCBI chr13:75,154,683...75,172,874
Ensembl chr13:75,154,684...75,172,874

G

forkhead box A1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of FOXA1 mRNA

NCBI chr 6:75,099,907...75,136,534
Ensembl chr 6:75,103,503...75,136,188

G

forkhead box P1

increases expression

Rifampin results in increased expression of FOXP1 mRNA

NCBI chr 4:131,559,599...132,155,092
Ensembl chr 4:131,564,756...132,112,258

G

fucosyltransferase 1

decreases expression

Rifampin results in decreased expression of FUT1 mRNA

NCBI chr 1:96,086,934...96,090,352
Ensembl chr 1:96,086,635...96,090,616

G

glucose-6-phosphatase catalytic subunit 1

multiple interactions
decreases expression
affects expression

[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA; INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]; SGK2 mutant form affects the reaction [Rifampin affects the expression of G6PC1 mRNA]; SGK2 mutant form inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin results in decreased expression of G6PC1 mRNA

PMID:24204015 PMID:34689256

NCBI chr10:86,307,400...86,318,766
Ensembl chr10:86,257,668...86,333,804

G

growth arrest and DNA-damage-inducible, alpha

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GADD45A mRNA

NCBI chr 4:96,154,789...96,157,091
Ensembl chr 4:96,154,789...96,157,115

G

growth arrest and DNA-damage-inducible, beta

multiple interactions

NR1I2 protein promotes the reaction [Rifampin results in increased expression of GADD45B mRNA]

NCBI chr 7:8,778,004...8,780,306
Ensembl chr 7:8,778,007...8,780,046

G

GATA binding protein 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of GATA5 mRNA

NCBI chr 3:167,418,563...167,426,751
Ensembl chr 3:167,418,565...167,426,751

G

glucokinase

decreases expression
multiple interactions

Rifampin results in decreased expression of GCK protein
NR1I2 protein promotes the reaction [Rifampin results in decreased expression of GCK protein]

NCBI chr14:80,785,060...80,829,842
Ensembl chr14:80,785,060...80,826,995

G

GLIS family zinc finger 2

increases expression

Rifampin results in increased expression of GLIS2 mRNA

NCBI chr10:10,951,157...10,978,524
Ensembl chr10:10,951,371...10,971,578

G

G protein subunit alpha L

decreases expression

Rifampin results in decreased expression of GNAL mRNA

NCBI chr18:60,622,311...60,762,599
Ensembl chr18:60,622,311...60,762,599

G

glutamic-oxaloacetic transaminase 1

multiple interactions
increases activity

[Rifampin co-treated with Isoniazid] results in increased activity of GOT1 protein
Rifampin results in increased activity of GOT1 protein

NCBI chr 1:242,357,293...242,381,535
Ensembl chr 1:242,357,306...242,380,633

G

glutamic--pyruvic transaminase

multiple interactions
increases activity
increases expression

4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of GPT protein]; [Rifampin co-treated with Acetaminophen] results in decreased activity of GPT protein
Rifampin results in increased activity of GPT protein
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPT protein; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]
[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein; [Rifampin co-treated with Isoniazid] results in increased activity of GPT protein; dendrobine inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased expression of GPT protein]; Rifampin inhibits the reaction [Acetaminophen results in increased expression of GPT protein]

PMID:24685772 PMID:25886055 PMID:27470132 PMID:31678598 PMID:32633153 More...

NCBI chr 7:108,416,646...108,419,495
Ensembl chr 7:108,416,642...108,419,494

G

glutathione peroxidase 2

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GPX2 mRNA; [Rifampin co-treated with Cobicistat] results in increased expression of GPX2 mRNA

PMID:21224054 PMID:33629115

NCBI chr 6:95,493,589...95,496,877
Ensembl chr 6:95,493,589...95,496,877

G

glutathione peroxidase 4

multiple interactions

[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]

NCBI chr 7:9,650,186...9,652,982
Ensembl chr 7:9,650,185...9,652,982

G

glutamate ionotropic receptor AMPA type subunit 1

decreases expression

Rifampin results in decreased expression of GRIA1 mRNA

NCBI chr10:41,210,713...41,527,283
Ensembl chr10:41,210,713...41,527,283

G

glutathione-disulfide reductase

increases activity

Rifampin results in increased activity of GSR protein

NCBI chr16:58,482,209...58,525,256
Ensembl chr16:58,482,505...58,525,661

G

glutathione S-transferase alpha 1

multiple interactions
increases expression

[Tetrachlorodibenzodioxin co-treated with Rifampin] results in increased expression of GSTA1 mRNA; Ketoconazole inhibits the reaction [Rifampin results in increased expression of GSTA1 mRNA]

PMID:16608920 PMID:19118567 PMID:29162470

NCBI chr 9:23,703,476...23,720,121
Ensembl chr 9:23,703,477...23,720,121

G

glutathione S-transferase mu 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM1 protein

NCBI chr 2:195,649,845...195,655,402
Ensembl chr 2:195,649,845...195,655,411

G

glutathione S-transferase, mu 5

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of GSTM3 mRNA

NCBI chr 2:195,531,599...195,534,562
Ensembl chr 2:195,531,495...195,534,553

G

glutathione S-transferase pi 1

multiple interactions
increases expression

[Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 mRNA; [Rifampin co-treated with Monocrotophos] results in increased expression of GSTP1 protein
Rifampin results in increased expression of GSTP1 mRNA; Rifampin results in increased expression of GSTP1 protein

NCBI chr 1:201,337,762...201,340,230
Ensembl chr 1:201,321,672...201,340,226

G

glutathione S-transferase theta 1

multiple interactions

GSTT1 gene polymorphism affects the susceptibility to [Isoniazid co-treated with Rifampin]; GSTT1 gene polymorphism results in increased susceptibility to [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide]

PMID:18397238 PMID:20485159

NCBI chr20:12,856,613...12,873,586
Ensembl chr20:12,856,669...12,873,585

G

GTF2I repeat domain containing 2

increases expression

Rifampin results in increased expression of GTF2IRD2 mRNA

NCBI chr12:22,497,767...22,536,455
Ensembl chr12:22,498,091...22,536,263

G

granzyme B

increases secretion

Rifampin results in increased secretion of GZMB protein

NCBI chr15:30,343,352...30,346,814
Ensembl chr15:30,173,603...30,346,814

G

heparin-binding EGF-like growth factor

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HBEGF mRNA

NCBI chr18:28,106,284...28,116,167
Ensembl chr18:28,105,760...28,116,441

G

histone deacetylase 3

multiple interactions

Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]

NCBI chr18:29,770,637...29,789,850
Ensembl chr18:29,770,636...29,793,856

G

histone deacetylase 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in decreased expression of HDAC5 mRNA

NCBI chr10:87,152,978...87,187,921
Ensembl chr10:87,152,978...87,188,235

G

hes-related family bHLH transcription factor with YRPW motif 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HEY1 mRNA

NCBI chr 2:93,096,605...93,100,316
Ensembl chr 2:93,095,498...93,100,312

G

hepatocyte growth factor

multiple interactions

HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased abundance of Reactive Oxygen Species]; HGF protein inhibits the reaction [[Isoniazid co-treated with Rifampin] results in increased activity of CASP3 protein]

NCBI chr 4:18,673,736...18,745,582
Ensembl chr 4:18,677,101...18,745,409

G

hypoxia inducible factor 1 subunit alpha

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of HIF1A mRNA
[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A mRNA; [Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of HIF1A protein; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of GPX4 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in decreased expression of SLC7A11 protein]; HIF1A protein affects the reaction [[Isoniazid co-treated with Rifampin co-treated with Pyrazinamide co-treated with Ethambutol] results in increased expression of GPT protein]

PMID:21127053 PMID:36878459

NCBI chr 6:92,624,059...92,669,262
Ensembl chr 6:92,624,390...92,669,261

G

high mobility group nucleosome binding domain 5

increases expression

Rifampin results in increased expression of HMGN5 mRNA

NCBI chr X:74,085,871...74,094,488
Ensembl chr X:74,085,875...74,094,441
Ensembl chr 1:74,085,875...74,094,441

G

heme oxygenase 1

multiple interactions
increases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HMOX1 mRNA
dorsomorphin inhibits the reaction [Rifampin results in increased expression of HMOX1 protein]
Rifampin results in increased expression of HMOX1 mRNA; Rifampin results in increased expression of HMOX1 protein
[arsenite co-treated with Rifampin] results in increased expression of HMOX1 mRNA

PMID:21224054 PMID:22159698 PMID:22258563 PMID:31678598

NCBI chr19:13,466,287...13,474,082
Ensembl chr19:13,467,244...13,474,079

G

hepatocyte nuclear factor 4, alpha

multiple interactions

[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA; [Rifampin co-treated with NR1I2 protein] results in decreased expression of HNF4A mRNA; [Rifampin results in increased activity of NR1I2 protein] inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; allyl isothiocyanate inhibits the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; allyl isothiocyanate inhibits the reaction [NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]]; NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; NR1I2 protein promotes the reaction [[HNF4A protein co-treated with Rifampin] results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [HNF4A protein binds to SULT1E1 enhancer]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]; Rifampin promotes the reaction [NR1I2 protein binds to HNF4A protein]; Rifampin promotes the reaction [PPARGC1A protein binds to HNF4A protein]

PMID:21127053 PMID:21292004 PMID:21764778 PMID:25069801

NCBI chr 3:152,186,787...152,248,320
Ensembl chr 3:152,186,787...152,248,320

G

histamine receptor H 1

increases expression

Rifampin results in increased expression of HRH1 mRNA

NCBI chr 4:147,564,963...147,649,353
Ensembl chr 4:147,645,995...147,647,455

G

heat shock protein family A (Hsp70) member 1 like

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA1L mRNA

NCBI chr20:3,848,843...3,855,571
Ensembl chr20:3,848,843...3,855,571

G

heat shock protein family A (Hsp70) member 5

multiple interactions
increases expression

ATF4 mutant form inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
[Rifampin co-treated with Cobicistat] results in increased expression of HSPA5 mRNA
4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 mRNA]; 4-phenylbutyric acid inhibits the reaction [Rifampin results in increased expression of HSPA5 protein]
Rifampin results in increased expression of HSPA5 mRNA; Rifampin results in increased expression of HSPA5 protein

PMID:24638036 PMID:27470132 PMID:32535746 PMID:33629115

NCBI chr 3:18,055,507...18,059,969
Ensembl chr 3:18,055,405...18,059,891

G

heat shock protein family A (Hsp70) member 8

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPA8 mRNA

NCBI chr 8:41,183,397...41,187,260
Ensembl chr 8:41,183,264...41,187,259

G

heat shock protein family B (small) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of HSPB1 mRNA

NCBI chr12:20,794,014...20,795,675
Ensembl chr12:20,794,028...20,795,743

G

heat shock protein family D (Hsp60) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPD1 mRNA

NCBI chr 9:56,579,195...56,590,011
Ensembl chr 9:56,579,201...56,589,662

G

heat shock protein family E (Hsp10) member 1

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of HSPE1 mRNA

NCBI chr 9:56,589,912...56,593,000
Ensembl chr 9:56,589,789...56,593,089

G

interferon gamma

increases secretion

Rifampin results in increased secretion of IFNG protein

NCBI chr 7:53,903,339...53,907,375
Ensembl chr 7:53,903,337...53,907,375

G

insulin-like growth factor binding protein 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP1 mRNA

NCBI chr14:82,047,415...82,052,482
Ensembl chr14:82,047,415...82,052,482

G

insulin-like growth factor binding protein 3

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP3 mRNA

NCBI chr14:82,056,347...82,064,083
Ensembl chr14:82,056,347...82,064,083

G

insulin-like growth factor binding protein 4

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of IGFBP4 mRNA

NCBI chr10:83,995,253...84,007,272
Ensembl chr10:83,989,591...84,007,225

G

interleukin 10

affects expression

Rifampin affects the expression of IL10 protein

NCBI chr13:42,472,625...42,477,308
Ensembl chr13:42,472,839...42,477,313

G

interleukin 12 receptor subunit beta 2

decreases expression

Rifampin results in decreased expression of IL12RB2 mRNA

NCBI chr 4:96,426,396...96,515,251
Ensembl chr 4:96,426,842...96,515,289

G

interleukin 13

increases secretion

Rifampin results in increased secretion of IL13 protein

NCBI chr10:37,790,130...37,792,687
Ensembl chr10:37,790,130...37,792,737

G

interleukin 18

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL18 mRNA

NCBI chr 8:50,904,630...50,932,887
Ensembl chr 8:50,906,960...50,932,887

G

interleukin 1 beta

multiple interactions
decreases expression

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in decreased expression of IL1B mRNA; Rifampin inhibits the reaction [Rotenone results in increased expression of and results in increased secretion of IL1B protein]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL1B mRNA]
Rifampin results in decreased expression of IL1B mRNA; Rifampin results in decreased expression of IL1B protein

PMID:21224054 PMID:25051504 PMID:26086368 PMID:31648047

NCBI chr 3:116,577,005...116,583,386
Ensembl chr 3:116,577,010...116,583,415

G

interleukin 6

decreases expression
multiple interactions
increases expression

Rifampin results in decreased expression of IL6 protein
Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]]; Rifampin inhibits the reaction [Rotenone results in increased expression of IL6 mRNA]
Rifampin results in increased expression of IL6 protein
[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of IL6 mRNA

PMID:21224054 PMID:21357946 PMID:25051504 PMID:31648047

NCBI chr 4:5,214,602...5,219,178
Ensembl chr 4:5,213,394...5,219,178

G

INO80 complex subunit D

decreases expression

Rifampin results in decreased expression of INO80D mRNA

NCBI chr 9:64,447,075...64,514,013
Ensembl chr 9:64,457,165...64,515,242

G

insulin 2

multiple interactions

INS protein inhibits the reaction [[Rifampin co-treated with NR1I2 protein] results in increased expression of G6PC1 mRNA]
Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPA protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPB protein]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of CEBPD mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA alternative form]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG mRNA]; Rifampin inhibits the reaction [[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Rosiglitazone co-treated with Indomethacin] results in increased expression of PPARG protein]

PMID:24204015 PMID:33412187

NCBI chr 1:197,843,277...197,992,522
Ensembl chr 1:197,843,281...197,864,775

G

integrator complex subunit 6

decreases expression

Rifampin results in decreased expression of INTS6 mRNA

NCBI chr15:36,908,966...37,048,043
Ensembl chr15:36,933,724...37,021,527

G

IQ motif containing with AAA domain 1

decreases expression

Rifampin results in decreased expression of IQCA1 mRNA

NCBI chr 9:90,626,735...90,742,563
Ensembl chr 9:90,626,744...90,742,618

G

integrin subunit beta like 1

decreases expression

Rifampin results in decreased expression of ITGBL1 mRNA

NCBI chr15:100,780,184...101,041,734
Ensembl chr15:100,780,184...101,041,733

G

Jun proto-oncogene, AP-1 transcription factor subunit

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of JUN mRNA

NCBI chr 5:109,894,175...109,897,268
Ensembl chr 5:109,893,145...109,897,656

G

kirre like nephrin family adhesion molecule 3

decreases expression

Rifampin results in decreased expression of KIRREL3 mRNA

NCBI chr 8:32,865,779...33,407,555
Ensembl chr 8:32,862,776...33,405,676

G

KLF transcription factor 2

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF2 mRNA

NCBI chr16:17,521,107...17,523,739
Ensembl chr16:17,514,552...17,523,944

G

KLF transcription factor 5

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF5 mRNA

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:76,064,258...76,079,445

G

KLF transcription factor 6

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of KLF6 mRNA

NCBI chr17:64,539,456...64,548,451
Ensembl chr17:64,531,463...64,588,570

G

low density lipoprotein receptor

increases expression

Rifampin results in increased expression of LDLR mRNA

NCBI chr 8:20,270,020...20,292,981
Ensembl chr 8:20,270,041...20,294,580

G

left right determination factor 1

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of LEFTY1 mRNA

NCBI chr13:92,649,226...92,659,722
Ensembl chr13:92,656,323...92,659,720

G

leptin

increases expression

Rifampin results in increased expression of LEP protein

NCBI chr 4:57,661,127...57,675,262
Ensembl chr 4:57,661,131...57,675,262

G

leukocyte receptor tyrosine kinase

increases expression

Rifampin results in increased expression of LTK mRNA

NCBI chr 3:106,734,675...106,741,552
Ensembl chr 3:106,734,676...106,743,369

G

MAF bZIP transcription factor F

multiple interactions

[Rifampin co-treated with NR1I2 protein] results in increased expression of MAFF mRNA

NCBI chr 7:110,912,367...110,923,711
Ensembl chr 7:110,912,499...110,923,851

G

microtubule-associated protein 1 light chain 3 beta

decreases metabolic processing
multiple interactions
increases lipidation

Rifampin results in decreased metabolism of MAP1LC3B protein
ATP6V0D1 protein affects the reaction [Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]]; Chloroquine promotes the reaction [Rifampin results in increased lipidation of MAP1LC3B protein]; Rifampin inhibits the reaction [Rotenone results in increased lipidation of MAP1LC3B protein]

PMID:29908302 PMID:31648047

NCBI chr19:49,665,795...49,673,655
Ensembl chr19:49,665,791...49,677,690
Ensembl chr16:49,665,791...49,677,690

G

mitogen-activated protein kinase 8

multiple interactions

Chloroquine inhibits the reaction [Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]]; Rifampin inhibits the reaction [Rotenone results in increased phosphorylation of MAPK8 protein]

NCBI chr16:8,638,897...8,721,960
Ensembl chr16:8,638,924...8,721,981

G

MAPK activated protein kinase 2

increases phosphorylation

Rifampin results in increased phosphorylation of MAPKAPK2 protein

NCBI chr13:42,513,762...42,560,061
Ensembl chr13:42,513,762...42,560,457

G

microtubule-associated protein, RP/EB family, member 3

increases expression

Rifampin results in increased expression of MAPRE3 mRNA

NCBI chr 6:25,513,800...25,558,876
Ensembl chr 6:25,513,800...25,558,881

G

matrilin 2

increases expression

Rifampin results in increased expression of MATN2 mRNA

NCBI chr 7:65,494,996...65,644,613
Ensembl chr 7:65,494,834...65,645,113

G

myelin basic protein

affects expression

Rifampin affects the expression of MBP mRNA

NCBI chr18:75,855,878...75,966,404
Ensembl chr18:75,855,878...75,966,404

G

MCL1 apoptosis regulator, BCL2 family member

multiple interactions

[Rifampin inhibits the reaction [CYP2C8 protein results in increased susceptibility to Amodiaquine]] which results in decreased expression of MCL1 protein

NCBI chr 2:183,219,137...183,235,676
Ensembl chr 2:183,219,220...183,222,303

G

MDM2 proto-oncogene

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC] results in increased expression of MDM2 mRNA

NCBI chr 7:53,290,660...53,315,205
Ensembl chr 7:53,290,664...53,314,915

G

mediator complex subunit 1

multiple interactions
decreases expression

Rifampin promotes the reaction [MED1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [MED1 protein binds to HNF4A protein]
Rifampin results in decreased expression of MED1 mRNA

PMID:21292004 PMID:22214767 PMID:24552687

NCBI chr10:83,145,538...83,189,260
Ensembl chr10:83,145,568...83,189,299

G

multiple inositol-polyphosphate phosphatase 1

increases expression

Rifampin results in increased expression of MINPP1 mRNA

NCBI chr 1:230,354,483...230,379,730
Ensembl chr 1:230,354,438...230,379,730

G

microRNA 143

increases expression

Rifampin results in increased expression of MIR143 mRNA

NCBI chr18:55,101,006...55,101,110
Ensembl chr18:55,101,006...55,101,110

G

microRNA 145

increases expression

Rifampin results in increased expression of MIR145 mRNA

NCBI chr18:55,099,640...55,099,727
Ensembl chr18:55,099,640...55,099,727

G

microRNA 148b

decreases expression

Rifampin results in decreased expression of MIR148B mRNA

NCBI chr 7:134,421,398...134,421,494
Ensembl chr 7:134,421,398...134,421,494

G

microRNA 15b

increases expression

Rifampin results in increased expression of MIR15B mRNA

NCBI chr 2:153,245,200...153,245,297
Ensembl chr 2:153,245,200...153,245,297

G

microRNA 186

multiple interactions

[Isoniazid co-treated with Rifampin] results in increased expression of MIR186 mRNA

NCBI chr 2:246,582,806...246,582,891
Ensembl chr 2:246,582,806...246,582,891

G

microRNA 192

decreases expression

Rifampin results in decreased expression of MIR192 mRNA

NCBI chr 1:203,564,946...203,565,055
Ensembl chr 1:203,564,946...203,565,055

G

microRNA 200a

increases expression

Rifampin results in increased expression of MIR200A mRNA

NCBI chr 5:166,648,494...166,648,582

G

microRNA 202

increases expression

Rifampin results in increased expression of MIR202 mRNA

NCBI chr 1:194,754,730...194,754,801
Ensembl chr 1:194,754,730...194,754,801

G

microRNA 204

increases expression

Rifampin results in increased expression of MIR204 mRNA

NCBI chr 1:220,316,931...220,317,040
Ensembl chr 1:220,316,931...220,317,040

G

microRNA 20b

increases expression

Rifampin results in increased expression of MIR20B mRNA

NCBI chr X:132,422,211...132,422,282
Ensembl chr X:132,422,211...132,422,282

G

microRNA 21

increases expression

Rifampin results in increased expression of MIR21 mRNA

NCBI chr10:71,405,257...71,405,348
Ensembl chr10:71,405,257...71,405,348

G

microRNA 212

decreases expression

Rifampin results in decreased expression of MIR212 mRNA

NCBI chr10:60,023,403...60,023,513
Ensembl chr10:60,023,403...60,023,513

G

microRNA 22

increases expression

Rifampin results in increased expression of MIR22 mRNA

NCBI chr10:60,307,039...60,307,133
Ensembl chr10:60,307,039...60,307,133

G

microRNA 26b

increases expression

Rifampin results in increased expression of MIR26B mRNA

NCBI chr 9:75,976,596...75,976,680
Ensembl chr 9:75,976,596...75,976,680

G

microRNA 296

decreases expression

Rifampin results in decreased expression of MIR296 mRNA

NCBI chr 3:163,051,838...163,051,915
Ensembl chr 3:163,051,838...163,051,915

G

microRNA 29a

decreases expression

Rifampin results in decreased expression of MIR29A mRNA

NCBI chr 4:59,650,608...59,650,695

G

microRNA 31

increases expression

Rifampin results in increased expression of MIR31 mRNA

NCBI chr 5:103,599,038...103,599,143

G

microRNA 328

increases expression

Rifampin results in increased expression of MIR328 mRNA

NCBI chr19:33,184,766...33,184,849
Ensembl chr19:33,184,766...33,184,849

G

microRNA 340-1

increases expression

Rifampin results in increased expression of MIR340 mRNA

NCBI chr10:34,393,568...34,393,665
Ensembl chr10:34,393,568...34,393,665

G

microRNA 34a

decreases expression

Rifampin results in decreased expression of MIR34A mRNA

NCBI chr 5:160,533,002...160,533,103
Ensembl chr 5:160,533,002...160,533,103

G

microRNA 374b

increases expression

Rifampin results in increased expression of MIR374B mRNA

NCBI chr X:68,591,732...68,591,799
Ensembl chr X:68,591,732...68,591,799

G

microRNA 532

decreases expression

Rifampin results in decreased expression of MIR532 mRNA

NCBI chr X:15,247,315...15,247,393
Ensembl chr X:15,247,315...15,247,393

G

microRNA 628

decreases expression

Rifampin results in decreased expression of MIR628 mRNA

NCBI chr 8:73,739,846...73,739,929
Ensembl chr 8:73,739,846...73,739,929

G

microRNA 652

decreases expression

Rifampin results in decreased expression of MIR652 mRNA

NCBI chr X:106,343,293...106,343,373
Ensembl chr X:106,343,293...106,343,373

G

microRNA 874

decreases expression

Rifampin results in decreased expression of MIR874 mRNA

NCBI chr17:6,620,649...6,620,724
Ensembl chr17:6,620,649...6,620,724

G

marker of proliferation Ki-67

multiple interactions

[Monocrotaline co-treated with Rifampin co-treated with Phenytoin co-treated with PRKDC gene mutant form] results in increased expression of MKI67 protein

NCBI chr 1:190,496,319...190,522,983
Ensembl chr 1:190,496,319...190,522,762

G

matrix metallopeptidase 3

decreases secretion

Rifampin results in decreased secretion of MMP3 protein

NCBI chr 8:4,640,397...4,653,963
Ensembl chr 8:4,640,416...4,653,961

G

myeloperoxidase

multiple interactions

Rifampin inhibits the reaction [Trinitrobenzenesulfonic Acid results in increased activity of MPO protein]

NCBI chr10:72,594,883...72,608,862
Ensembl chr10:72,594,661...72,604,819

G

major histocompatibility complex, class I-related

affects expression

Rifampin affects the expression of MR1 mRNA

NCBI chr13:67,298,362...67,317,985
Ensembl chr13:67,299,585...67,317,970

G

microsomal triglyceride transfer protein

decreases expression

Rifampin results in decreased expression of MTTP mRNA

NCBI chr 2:226,613,090...226,654,239
Ensembl chr 2:226,613,090...226,654,239

G

myosin heavy chain 6

increases expression

Rifampin results in increased expression of MYH6 mRNA

NCBI chr15:28,418,120...28,442,316
Ensembl chr15:28,417,616...28,441,720

G

nuclear assembly factor 1 ribonucleoprotein

decreases expression

Rifampin results in decreased expression of NAF1 mRNA

NCBI chr16:22,837,583...22,868,320
Ensembl chr16:22,837,588...22,868,293

G

nucleosome assembly protein 1-like 5

increases expression

Rifampin results in increased expression of NAP1L5 mRNA

NCBI chr 4:88,022,670...88,024,988
Ensembl chr 4:88,022,569...88,024,654

G

nuclear receptor coactivator 1

multiple interactions

Camptothecin inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Itraconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Ketoconazole inhibits the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Miconazole promotes the reaction [Rifampin results in increased expression of NCOA1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein co-treated with Rifampin] results in decreased expression of SLC22A1 mRNA]; NCOA1 protein inhibits the reaction [[NR1I2 protein results in increased susceptibility to Rifampin] which results in decreased expression of SLC22A1 mRNA]; oxiconazole promotes the reaction [Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; pazopanib inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; pimecrolimus inhibits the reaction [Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]]; Rifampin inhibits the reaction [NCOA1 protein binds to SLC22A1 promoter]; Rifampin inhibits the reaction [oxiconazole promotes the reaction [NR1I2 protein binds to NCOA1 protein]]; Rifampin promotes the reaction [[NCOA1 protein binds to NR1I2 protein] which results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [[NR1I2 protein binds to NCOA1 protein] which binds to CYP27A1 gene]; Rifampin promotes the reaction [NCOA1 protein binds to and results in increased activity of NR1I2 protein]; Rifampin promotes the reaction [NCOA1 protein binds to HNF4A protein]; Rifampin promotes the reaction [NCOA1 protein binds to NR1I2 protein]; Rifampin promotes the reaction [NR1I2 protein binds to NCOA1 protein]

PMID:11581012 PMID:12072427 PMID:16819505 PMID:17088262 PMID:17438109 More...

NCBI chr 6:27,232,609...27,507,992
Ensembl chr 6:27,232,611...27,475,664

G

nuclear receptor coactivator 2

multiple interactions

Rifampin promotes the reaction [NCOA2 protein binds to HNF4A protein]

NCBI chr 5:5,835,642...6,069,693
Ensembl chr 5:5,835,706...6,067,451

G

nuclear receptor coactivator 6

multiple interactions

NCOA6 promotes the reaction [Rifampin promotes the reaction [[HNF4A co-treated with NR1I2] results in increased expression of CYP2C9 mRNA]]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP2C9 mRNA]; Rifampin promotes the reaction [[HNF4A co-treated with NCOA6] results in increased expression of CYP3A4 mRNA]; Rifampin promotes the reaction [NCOA6 protein binds to HNF4A protein]

NCBI chr 3:143,890,896...143,961,916
Ensembl chr 3:143,890,896...143,952,268

G

nuclear receptor co-repressor 1

multiple interactions

Rifampin inhibits the reaction [NCOR1 protein binds to and results in decreased activity of NR1I2 protein]

NCBI chr10:46,999,536...47,142,294
Ensembl chr10:46,999,536...47,141,032

G

nuclear receptor co-repressor 2

multiple interactions

[NR1I2 protein binds to NCOR2 protein] inhibits the reaction [Rifampin results in increased expression of CYP3A4 mRNA]; Rifampin inhibits the reaction [NCOR2 protein binds to and results in decreased activity of NR1I2 protein]; Rifampin inhibits the reaction [NCOR2 protein binds to NR1I2 protein]; Rifampin inhibits the reaction [NR1I2 protein binds to NCOR2 protein]; Rifampin inhibits the reaction [trichostatin A inhibits the reaction [[PIAS1 co-treated with SUMO3] inhibits the reaction [NCOR2 protein promotes the reaction [NR1I2 protein binds to HDAC3 protein]]]]; Rifampin promotes the reaction [NR1I2 protein binds to NCOR2 protein]

PMID:12072427 PMID:22214767 PMID:25313206 PMID:26883953 PMID:28289823 More...

NCBI chr12:31,466,418...31,628,319
Ensembl chr12:31,466,412...31,628,319

G

NFE2 like bZIP transcription factor 2

increases expression
multiple interactions
decreases expression
decreases activity

Rifampin results in increased expression of NFE2L2 protein
[tanshinone co-treated with Rifampin] results in increased expression of NFE2L2 mRNA; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 mRNA]; tanshinone inhibits the reaction [Rifampin results in decreased expression of NFE2L2 protein]
Rifampin results in decreased expression of NFE2L2 mRNA; Rifampin results in decreased expression of NFE2L2 protein
Rifampin inhibits the reaction [arsenite results in increased activity of NFE2L2 protein]
Rifampin results in decreased activity of NFE2L2 protein

PMID:31678598 PMID:33307820 PMID:33412187

NCBI chr 3:60,594,239...60,621,712
Ensembl chr 3:60,594,242...60,621,737

G

nuclear transcription factor Y subunit alpha

decreases expression

Rifampin results in decreased expression of NFYA mRNA

NCBI chr 9:12,587,437...12,613,911
Ensembl chr 9:12,586,259...12,613,898

G

NLR family, pyrin domain containing 3

multiple interactions

Rifampin inhibits the reaction [Rotenone results in increased expression of NLRP3 protein]